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ABSTRACT 
 
WILLIAM EDWARD FUNK: Protein Adducts as Measures of Exposure in Epidemiological 
Research 
(Under the direction of Stephen M. Rappaport) 
 
 
Protein adducts can serve as biomarkers of exposure to variety of xenobiotic toxicants and 
reactive endogenous species. However, despite their utility as exposure biomarkers, protein 
adducts have rarely been used in epidemiology. One reason for this is the cost and difficulty of 
obtaining blood samples, which frequently limits the uses of protein adducts as measures of 
exposure in large-scale studies. In addition, protein adducts are typically low in abundance 
compared with unmodified proteins, and are thus often difficult to detect in human blood. This 
research developed two novel methods that address these limitations in current assays of blood-
protein adducts. First, to make blood proteins more accessible to epidemiologic studies, a method 
was developed to measure protein adducts in dried blood spots (DBS). Because DBS are easier 
to collect and store than conventional venous blood samples, they encourage applications of 
biomarkers of exposure in population studies. In addition, neonatal DBS which are collected 
from virtually all live births in the U.S. can be used to investigate chemical exposures in utero. 
Second, to increase analytical sensitivity for detecting less-abundant adducts, a method was 
developed to enrich cysteinyl adducts of human serum albumin (HSA).  Because the major site 
of adduction of HSA is the single free sulfhydryl group located at Cys34, the enrichment 
approach utilized the propensity of mercaptalbumin (i.e., unadducted HSA) to bind with thiol-
affinity resins. Furthermore, because the most common adducts of HSA-Cys34 are mixed 
iii 
 
disulfides formed by reversible reactions between Cys34 and serum thiols (notably cysteine), 
mixed disulfides were liberated via reduction with dithiothreitol (DTT) prior to removing 
mercaptalbumin with thiol affinity resins. These two methods provide a straightforward approach 
for obtaining and processing blood specimens so as to promote the use of protein adducts as 
biomarkers of exposure in epidemiologic investigations.  
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1. Background and Significance 
 
1.1. Exposure assessment 
1.1.1. Historical background  
The science of exposure assessment involves the estimation of parameters to characterize 
the distributions of environmental and/or biological levels of toxicants across exposed 
populations, along with statistical evaluation and interpretation of such parameter estimates 
(Rappaport and Kupper 2008). Quantitative exposure assessment has its roots in industry, where 
workers in the early 20th century exposed to certain chemical toxicants were deemed at risk for 
occupational diseases (Rappaport and Kupper 2008). The increased risk in this population 
motivated governments to set occupational exposure limits to protect workers. In 1946 Threshold 
Limit Values were established for 150 different chemicals (LaNier 1984). To test for compliance 
air sampling strategies were developed to measure levels of airborne toxicants within the 
breathing zones of the workers. However, static air measurements often underestimated worker 
exposures. This complication led to the use of personal samplers in the 1950s, a method that 
better reflects the levels of chemical toxicants to which workers are truly exposed (Cherrie 
2003).  
Since the 1950s, exposure assessment has moved beyond the workplace to environmental 
settings. With growing concern and awareness of elevated pollution levels, especially within 
major cities, legislation has been passed to regulate chemical emissions in the outdoor 
environment. The United States enacted a series of clean air acts starting in 1955 that has 
resulted in substantial reduction in air pollution, especially during the past three decades 
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(Elichegaray, Bouallala et al. 2009). Despite these reductions, the state of the science 
shows that significant health effects remain as evidenced by epidemiological studies that relate 
exposures to ambient air pollution and non-accidental mortality (Dockery and Pope 1994; 
Schwartz and Morris 1995; Dominici, Zeger et al. 2000). Thus, ambient air monitoring is critical 
for air regulatory processes and continues to be an important tool to estimate human exposures to 
environmental toxicants. 
1.1.2. Air measurements versus biomarkers  
When inhalation is the primary exposure route for a chemical toxicant, exposure 
estimates can be derived from measurements of air concentrations (Cherrie 2003). Air 
measurements can often be made with relative ease and low cost, thus permitting large numbers 
of measurements to be obtained. However, the large variability in air measurements over-time 
can bias their use as surrogates of exposure when estimating exposure-response relationship 
(Lin, Kupper et al. 2005; Scheepers 2008).  
One alternative to air measurements is biological monitoring, which involves 
quantification of exogenous compounds, or their products, within accessible biological matrixes 
such as blood, breath, and urine (Rothman, Stewart et al. 1995; Mutti 1999). Lin et al. reported 
that biological measurements typically have smaller intraindividual variability than the 
corresponding air measurements and thus provide less biasing estimates of true exposure levels 
(Lin, Kupper et al. 2005). Furthermore, biomarkers also account for all exposure routes (e.g. air, 
dermal, and ingestion), and capture inter-individual differences in metabolism and uptake, which 
are missed with air measurements (Rappaport, Symanski et al. 1995; Bartsch 2000; Sabbioni and 
Jones 2002).  
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1.1.3. Biomarkers in epidemiological research 
The term epidemiology is derived from the Greek word epidemios, and literally means 
"the study of what is upon the people". Within this framework, environmental epidemiology 
examines the relationship between levels of environmental exposure with human diseases 
(Scheepers 2008). One major limitation of epidemiology has been the lack of statistical power to 
associate exposures with disease outcomes due to exposure misclassification (Benke, Sim et al. 
2001). Traditionally, epidemiologists have relied upon surrogate exposure measures, such as 
self-reported exposures and nonspecific measures such as “…time living within a contaminated 
environment” (Sim 2002). These exposure estimates can be grossly inaccurate and often fail to 
reflect the degree and nature of true exposures.  
To surmount this limitation, epidemiology has increasingly turned to biomarkers as 
exposure surrogates (Wild 2009). Biomonitoring provides a more reliable estimate of internal 
dose, which decreases the likelihood of exposure misclassification (Lin, Kupper et al. 2005). 
However, biomarkers have limitations in epidemiological research. Because environmental 
toxicants tend to be chemically reactive species, their short life spans in vivo make them difficult 
to measure directly within biological specimens. As a result, exposures can be underestimated 
when sampling fails to occur within these narrow measurement windows. This shortcoming has 
motivated the use of stable adducts of these compounds with abundant blood proteins as 
exposure biomarkers. 
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1.2. Protein adducts  
1.2.1. Background 
Elizabeth and James Miller first observed the formation of addition products between 
small electrophiles and proteins in the late 1940s (Miller 1947). These investigations 
demonstrated that when rats were dosed with the hepatic carcinogen, p-
dimethylaminoazobenzene, metabolites of this chemical would bind tightly to cellular 
constituents, which the investigators hypothesized to be liver proteins. Although it was not yet 
recognized at this time that cellular DNA was the target of genotoxic carcinogens, this hallmark 
study recognized the importance of metabolism in chemical carcinogenesis, and was the first 
report of protein adducts.  
Chemical carcinogenesis is thought to be initiated by modification of DNA by genotoxic 
carcinogens (Turesky and Vouros 2004).  DNA is not, however, the only target site of reactive 
electrophiles in vivo. For example, alkylating agents that can modify DNA share similar reaction 
kinetics with nucleophilic residues on proteins (Ross 1962). Studies in the 1970s motivated the 
use of protein adducts as biomarkers of carcinogen dose (Groth and Neumann 1972; Ehrenberg, 
Hiesche et al. 1974). Protein adducts offer several advantages over DNA adducts as exposure 
biomarkers. First, proteins are much more abundant than DNA in blood (hemoglobin ~150 
mg/ml, serum albumin ~30 mg/ml, DNA ~0.005 mg/ml) (Tornqvist, Fred et al. 2002). Second, 
unlike DNA adducts, protein adducts are not subject to excision repair processes –this leads to 
simpler calculations of systemic dose (Skipper and Tannenbaum 1990).  
Protein adducts can also be used as biomarkers of noncarcinogenic toxicity (Lopachin 
and Decaprio 2005) as illustrated by the examples in Table 1.1. Other mechanisms that do not 
directly involve adduct formation, such as oxidative stress, can also contribute to cellular 
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damage. Since exposure to electrophilic compounds can lead directly and indirectly to the 
production of reactive oxygen species, adducts of these species can serve as indirect exposure 
biomarkers (Fabisiak, Sedlov et al. 2002; Lang, Figueroa et al. 2004).  Thus, protein adducts can 
serve as biomarkers in a host of applications. 
 
Table 1.1.  Examples of chemical toxicants that form protein adducts and their organ-
specific targets. 
    
 
Assays of protein adducts have focused upon hemoglobin (Hb) and human serum 
albumin (HSA), the most abundant protein in blood and plasma, respectively (Tornqvist and 
Kautiainen 1993). Stable adducts accumulate during the mean residence time of the protein, 
which allows the integration of exposure over relatively long periods of time. Hemoglobin has a 
life span of 120 days which is equivalent to the life span of erythrocytes, the cells in which Hb is 
contained (Ehrenberg, Moustacchi et al. 1983). Consequently, Hb clearance follows zero-order 
elimination kinetics. In contrast, HSA turnover is independent of the age of the individual protein 
molecules and follows first-order elimination kinetics with a half-life of 20-25 days (Skipper and 
Tannenbaum 1990). Figure 1.1 illustrates protein adduct elimination profiles for HSA and Hb 
Chemical Toxicant Organ System Toxicity
acrolein neurotoxicity
acrylamide neurotoxicity
allylamine cardiotoxicity
2-methylfuran renal toxicity
N-acetyl-p-benzoquinone hepatotoxocity
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following an acute chemical exposure. Using these elimination parameters, mathematical 
properties of both proteins as chemical dosimeters have been derived (Ehrenberg, Moustacchi et 
al. 1983; Sabbioni, Skipper et al. 1987).  
 
                                   
   
 
1.2.2. Protein adduct chemistry 
Protein adducts are covalent modifications that are formed via reactions between small 
reactive electrophiles and nucleophilic protein targets. Electrophilic species are characterized as 
compounds that contain regions of low electron density, whereas nucleophilic targets consist of 
amino acid residues containing heteroatoms with increased electron density (namely oxygen, 
nitrogen, and sulfur) (Tornqvist, Fred et al. 2002; Parthasarathi, Subramanian et al. 2004). HSA 
and Hb contain numerous nucleophilic sites, including the thiols of cysteine residues, carboxylic 
acid moieties of aspartic acid, glutamic acid, and the C-terminus; the amine groups of histidine, 
lysine, tryptophan, and the N-terminus; and the hydroxyl groups of serine and tyrosine 
(Tornqvist, Fred et al. 2002). Electrophiles can react with nucleophiles by multiple mechanisms, 
t
HSA Hb
A0/2
A(t)
20 days
63 days
160 days
20 days 63 days 160 days
Figure 1.1.  Protein adduct elimination profiles for HSA and Hb following an 
acute chemical exposure. A denotes adduct level, where A0 is the initial adduct 
level after an acute exposure, and A(t) is the level of adducts at time t (Adapted 
from Tornqvist et. al, 1993). 
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including SN1 and SN2 substitution, 1,4-addition, Schiff-base formation, and radical-mediated 
reactions (Tornqvist, Fred et al. 2002). Of these, substitution mechanisms are most common. 
Second-order reaction rates of electrophiles with nucleophilic targets can be estimated using the 
Swain-Scott empirical relationship 
 
                                                  log (kY/kH2O) = sn                                             Eq. 1.1. 
 
where kY is the rate constant of reaction between a given electrophile and nucleophile (Y), 
relative to the electrofile reactivity with water (kH2O), s is the selectivity constant, and n is the 
strength of the nucleophile (Swain and Scott 1953). Reaction rates generally increase in line with 
s, where the reactivity of nucleophilc sites on the protein follows the order O<N<S (Ross 1962). 
As such, protein sulfhydryls (namely the sulfur atoms of cysteine) tend to be the most 
nucleophilic sites on proteins. In addition to the physico-chemical nature of the nucleophile, the 
reactivity of a nucleophilic site is also governed by the microenvironment within the protein. As 
such, the tertiary structure of the protein, and the proximity with neighboring amino acid 
residues, can lead to steric shielding and alterations to the electronic properties of the 
nucleophile, which can in turn alter the reactivity (Lopachin and Decaprio 2005; Stewart, 
Blindauer et al. 2005).  
1.2.3. Protein adducts as exposure biomarkers 
Many classes of compounds and/or their reactive metabolites react with proteins to form 
adducts. These electrophilic groups are summarized in Table 1.2. Many analytical strategies have 
been employed to detect protein adducts, including laser-induced fluorescence (Weiss 1999; 
Ozbal, Skipper et al. 2000) and immunochemical approaches (Poirier 1984; Santella 1988; van 
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Welie, van Dijck et al. 1992). However, the most common analytical approach to detect protein 
adducts employs mass spectrometry (Rubino, Pitton et al. 2009). Sensitive gas 
chromatography/mass spectrometry (GC/MS) methods have been developed to identify and 
quantify specific adducts (Waidyanatha, Lin et al. 1996; Yeowell-O'Connell, Jin et al. 1996; 
Waidyanatha, Yeowell-O'Connell et al. 1998; Yeowell-O'Connell, Rothman et al. 1998; 
Rappaport and Yeowell-O'Connell 1999; Waidyanatha, Troester et al. 2002; Aronson, Bartha et 
al. 2004).  Since analytes must be volatile in GC/MS experiments, these methods require that 
adducts (or modified amino acids) be cleaved and isolated from the protein prior to analysis. In 
addition, adducts are often derivatized to enhance volatility and sensitivity. For example, the 
derivatization of quinone adducts using trifluoracetic anhydride to produce trifluorothioacetates, 
can be detected using negative-ion-chemical-ionization (NICI) mode with GC/MS 
(Waidyanatha, Yeowell-O'Connell et al. 1998).  
Recent advances in liquid chromatography/mass spectrometry (LC/MS) technologies 
have greatly improved the ability to detect protein adducts of modified proteins, peptides, and 
amino acids (reviewed in (Rubino, Pitton et al. 2009)). In addition, various ionization techniques, 
such as electrospray ionization (ESI) and atmospheric pressure ionization (API), coupled with 
tandem mass spectrometry have enabled researchers to detect and identify protein adducts 
without the volatility restraints of GC/MS methods (Johnstone and Rose 2001).   
Although many assays have been developed to measure protein adducts, one major 
impediment to the use of protein adducts in large-scale environmental studies remains the cost 
and difficulty of obtaining blood samples (Funk, Waidyanatha et al. 2008). Traditional protein 
adduct assays require trained phlebotomists to draw venous blood samples, a procedure that is 
both invasive and costly. In addition, once blood samples have been obtained, immediate field 
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processing is often required to separate the red cells (containing Hb) from the plasma (containing 
HSA), prior to freezing and transporting specimens for analysis. This impediment has motivated 
the use of dried blood spots for blood collection (Couzin-Frankel 2009). 
 
Table 1.2.  Classes of compounds and/or their reactive metabolites that react with proteins 
through various mechanisms to form adducts. 
                         
 
1.3. Dried blood spots 
1.3.1. Newborn dried blood spots 
Guthrie and Susi first used filter paper for the collection and analysis of drops of whole 
blood to screen newborns for hyperphenylalaninemia, a condition associated with the genetic 
disease phenylketonuria (Guthrie and Susi 1963). This innovative and simple blood collection 
technique fostered a national newborn screening program in the United States, where today more 
than 98% of live births are screened for treatable metabolic diseases (Olshan 2007). Recent 
Electrophilic Agent Class Examples Mechanism
Alkylating and arylating Alkyl halides Nucleophilic substitution
Oxiranes Nucleophilic substitution
Alkynitrosamides Nucleophilic substitution
Alkylnitrosamines Nucleophilic substitution
Dialkyl sulfates Nucleophilic substitution
Alkyl alkanesulfonates Nucleophilic substitution
Quinones 1,4-Addition
Electrophilic nitrogen 
species
Aromatic amines Nucleophilic substitution
Carbonyl compounds Aldehydes Schiff base
Acylating Organic acid anhydrides Nucleophilic substitution 
or addition
Phosphorylating Organo phosphorous 
compounds
Nucleophilic substitution
Metal ions Beryllium (II) Multiple mechanisms
Free radicals Hydroxyl radical Radical-mediated 
reactions
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advancements in analytical capabilities, i.e. tandem mass spectrometry, have greatly increased 
the number of disorders that screening laboratories can detect. For example, the State Laboratory 
of Public Health in North Carolina uses newborn dried blood spots (DBS) collected on Guthrie 
cards to screen newborns for more than 35 disorders (Table 1.3.).  
 
Table 1.3.   Metabolic disorders screened by the State Laboratory Pubic Health in North 
Carolina as of 2008. 
      
(http://slph.ncpublichealth.com/Newborn/DisordersTested.asp, 2009) 
 
The Newborn Screening Quality Assurance Program (NSQAP) at the Center for Disease 
Control and Prevention (CDC) has provided technical support and assistance for DBS specimen 
collection to more than 215 laboratories in 37 countries over the past 25 years (Mei, Alexander et 
al. 2001). This effort has helped to achieve better consistency in blood collection among 
laboratories and has worked to assure stringent quality control with the blood collection 
Argininosuccinic aciduria
Citrullinemia
Homocystinuria (cystathionine beta synthase) 
Maple syrup urine disease / Branched-chain ketoacid
dehydrogenase
Phenylketonuria / Hyperphenylalaninemia
Tyrosinemia type II 
Tyrosinemia type III 
Glutaric acidemia type I 
Multiple carboxylase deficiency 
3-Hydroxy-3-methylglutaryl-CoA lyase deficiency 
Isobutyryl-CoA dehydrogenase deficiency 
Isovaleric acidemia / Isovaleryl-CoA dehydrogenase
deficiency 
Beta-ketothiolase (BKT) / Short-chain keto
acylthiolase deficiency 
Methylmalonic aciduria
2-Methylbutyryl-CoA dehydrogenase deficiency 
3-Methylcrotonyl-CoA carboxylase deficiency 
Propionic acidemia
Carnitine/acylcarnitine translocase deficiency 
Carnitine palmitoyltransferase II deficiency 
Medium-chain acyl-CoA dehydrogenase deficiency 
Multiple acyl-CoA dehydrogenase deficiency 
Long-chain 3-hydroxyacyl-CoA dehydrogenase
deficiency 
Short-chain acyl-CoA dehydrogenase deficiency 
Trifunctional protein deficiency 
Very long-chain acyl-CoA dehydrogenase deficiency 
Biotinidase deficiency 
Congenital adrenal hyperplasia 
Galactosemia/ galactose-1-phosphate uridyl
transferase deficiency 
Primary congenital hypothyroidism 
Hemoglobin C disease 
Hemoglobin E disease 
Sickle cell disease 
Sickle/hemoglobin C disease 
Sickle/hemoglobin E disease 
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products. The Whatman series specimen collection paper used for newborn screening has been 
rigorously evaluated by the Newborn Screening Quality Assurance Program using an isotope 
doping method to characterize chromatographic, hematocrit, and blood volume effects (Mei, 
Alexander et al. 2001). Quality assurance issues concerning collection, transport, and storage of 
DBS have also been addressed. To assure consistency between lots of specimen collection cards, 
all lots are routinely evaluated by NSQAP to verify compliance within established guidelines, 
thus providing consistency in specimen collection between newborn screening laboratories. 
1.3.2. Dried blood spots in environmental research 
In many states, newborn DBS are stored for extended periods of time in case re-analysis 
is needed (Couzin-Frankel 2009). These DBS archives create opportunities in molecular 
epidemiology for retrospective studies. A review article by Mei et al. in 2001 reported more than 
160 biomarkers that have been detected in dried blood spots (Mei, Alexander et al. 2001). More 
recently, researchers have used DBS to screen for genetic abnormalities including cystic fibrosis 
and hemoglobinopathies (Enevold, Vestergaard et al. 2005; Enevold, Nkya et al. 2007). DBS 
have also been used in adolescent and adult populations to measure C-reactive protein and 
glycosylated hemoglobin, anti-malarial antibodies, and HbA1c (McDade, Burhop et al. 2004; 
Corran, Cook et al. 2008; Lomeo, Bolner et al. 2008). In fact, a Pub Med search of “dried blood 
spots” identified more than 350 peer-reviewed papers that have been published since the 2001 
publication of Mei et al.  
The recent explosion in the use of DBS to screen human populations stems from several 
advantages that DBS offer over venous blood collection. Blood collection by heel or finger prick 
is less invasive than venipuncture. Collection of DBS does not require a trained phlebotomist, 
which drastically decreases the cost of obtaining blood specimens in population-based studies. 
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Also, DBS can be dried and transported in flat envelopes via standard mail, and long-term 
storage of DBS requires substantially less space than frozen whole blood or fractionated-blood 
samples. These advantages have motivated the use of DBS in a large number of population-
based surveys (table 1.4.) (McDade, Williams et al. 2007).  
                    
   Table 1.4.  Large population-based surveys conducted using DBS. (Adapted from  
McDade et al. 2007) 
 
 
1.3.3. Protein adducts in dried blood spots 
The use of DBS to develop assays that measure protein adducts as exposure biomarkers is 
attractive for large-scale epidemiological studies. Protein adducts in newborn DBS are of 
particular interest because they afford the opportunity to measure prenatal exposures to chemical 
toxicants using archived newborn specimens. Since adducts accumulate over the life span of a 
protein, protein adducts in newborn DBS permit assessment of an integration of exposure over a 
relatively wide exposure window. For example, the 120-day life span of Hb allows estimation of 
newborn exposures to adducting species during a substantial span of fetal development [note that 
Study N Biomarkers Measured Study Website
Great Smokey Mountains 
Study
1,071 Androstenedione, DHEA-S, EBV 
antibodies, estradiol, FSH, LH, 
testosterone
http://devepi.mc.duke.edu/GSMS.html
Health and Retirement Study 7,000 CRP, HBA1c, total cholesterol, HDL http://hrsonline.isr.umich.edu
Los Angeles Family and 
Neighborhood Survey
5,000 CRP, EBV antibodies, HBA1c, total 
cholesterol, HDL
http://www.lasurvey.rand.org
National Longitudinal Study 
of Adolescent Health
17,000 CRP, EBV antibodies, HBA1c http://www.cpc.unc.edu/addhealth
National Social Life, Health, 
andAging Study
1,945 CRP, EBV antibodies, HBA1c, 
hemoglobin
http://www2.norc.org/nshap
Study of the Tsunami 
Aftermath and Recovery 
35,000 CRP, EBV antibodies http://chd.ucla.edu/STAR/STAR.html
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the fetal Hb variant is reported to have a similar half-life as the adult variant] (Brace, 
Langendorfer et al. 2000).This feature is of particular importance because fetal life and early 
infancy are developmental periods of heightened susceptibility to environmental hazards 
(Grandjean, Bellinnger et al. 2007). Factors that put the fetus at higher risk include greater cell 
proliferation rates, greater number of cells with heightened risk, decreased immunologic 
competence, and lower capacity to detoxify chemical toxicants and repair DNA (Anderson, 
Diwan et al. 2000). Consequently, chemical exposures during these sensitive developmental 
windows can result in increased risk for disease and disabilities in infants and children. Protein 
adducts in DBS offer valuable opportunities for investigating such chemical exposures in utero 
and their possible links to adverse health outcomes.  
 
1.4. Adducts of HSA-Cys34  
1.4.1. Human serum albumin  
Human serum albumin (HSA) is the most abundant protein in plasma and represents 
approximately 60% of total plasma proteins (Kawakami, Kubota et al. 2006). Produced in the 
liver, HSA is a single-chain biopolymer consisting of 585 amino acid residues that make up three 
homologous domains (I, II, and III), subdivided into two subdomains (A and B) (Stewart, 
Blindauer et al. 2005). HSA has a total of 35 cysteines, with 34 of the residues intramolecularly 
bond as disulfides (Suji and Sivakami 2008). The single remaining free cysteine, Cys34, 
represents the largest fraction of free thiol in plasma (Fabisiak, Sedlov et al. 2002). Within the 
tertiary protein structure of HSA, Cys34 resides in a unique micro-molecular environment close 
to three ionizable residues: Asp38, His39, and Tyr84 (Figure 1.2.) (Stewart, Blindauer et al. 2005). 
As a result, Cys34 has an unusually low pKa and exists primarily in its more reactive thiolate 
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form. Despite this fact, crystallographic studies show that Cys34 is buried in a crevice 
approximately 9.5 Å deep, which limits its accessibility (Stewart, Blindauer et al. 2005). 
Consequently, HSA-Cys34 is heterogeneous with respect to redox status, and exists both in the 
reduced and oxidized forms. 
 
        
Figure 1.2.  The micro-molecular environment of HSA-Cys34. Three ionisable residues: 
Asp38, His39, and Tyr84, are responsible for Cys34’s unusually low pKa. 
 
 
1.4.2. Biological role of HSA 
 HSA has several biological functions, including the maintenance of colloidal osmotic 
pressure, binding and transport of endogenous compounds, and scavenging of reactive 
inflammatory mediators (Lang, Figueroa et al. 2004; Ogasawara, Namai et al. 2006; Ogasawara, 
Mukai et al. 2007; Marjolaine, Rondeau et al. 2008). The Cys34 residue of serum albumin is 
highly conserved across all mammalian species (Stewart, Blindauer et al. 2005), which suggests 
that Cys34 is an essential residue involved in the physiological function of HSA. A variety of 
compounds have been reported that bind with HSA-Cys34. In the circulating plasma, HSA-Cys34 
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forms disulfides with free cysteine, glutathione, and homocysteine (Beck, Ambahera et al. 2004). 
It also transports over 80% of nitric oxide in blood as Cys34-S-nitrosothiol (Stamler, Jaraki et al. 
1992). In addition, HSA-Cys34 is the binding site for clinically important exogenous compounds, 
such as gold(I) antiarthritic drugs, platinum(II) anticancer drugs, and mercurial drugs (Malik, 
Otiko et al. 1980; Roberts, Xiao et al. 1996; Ross, Carr et al. 2000; Stewart, Blindauer et al. 
2005; Timerbaev, Hartinger et al. 2006). Other drugs that bind with Cys34 through disulfide 
linkages include the antihypertensive drug, Captopril, and the alcohol-abuse drug, Disulfuram 
(Agarwal, McPherson et al. 1983; Keire, Mariappan et al. 1993). 
 HSA-Cys34 redox state correlates with health status, where a higher degree of oxidation 
has been reported in cases of hepatic diseases (Watanabe, Matsuzaki et al. 2004), diabetes 
(Suzuki, Yasuda et al. 1992), renal diseases (Soejima, Matsuzawa et al. 2004), aging (Era, 
Kuwata et al. 1995), and fatigue (Imai, Hayashi et al. 2002). The major structural change found 
in higher oxidized HSA is the formation of the mixed disulfides between Cys34 and free cysteine 
(Kawakami, Kubota et al. 2006). 
1.4.3. HSA-Cys34 adducts as exposure biomarkers 
HSA-Cys34 is frequently modified by electrophilic xenobiotic species and/or their 
reactive metabolites (Farmer 1995). As such, the HSA-Cys34 adductome has been used 
extensively in exposure assessment. One of the first applications of protein adducts as exposure 
biomarkers was as a surrogate to measure exposure to genotoxic chemical carcinogens (Groth 
and Neumann 1972; Ehrenberg, Hiesche et al. 1974). In these studies, levels of HSA-Cys34 
modification were employed to quantify in vivo carcinogen dose. More recent studies have 
shown strong correlations between adduct concentrations and occupational and environmental 
exposures. For example, log-scale scatter plots are provided in Figure 1.3. of HSA-Cys34 adducts 
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of benzene oxide (BO) and 1,4-benzoquinone (1,4-BQ), versus personal benzene exposure for 
439 Chinese workers (Yeowell-O'Connell, Rothman et al. 2001; Rappaport, Waidyanatha et al. 
2002; Lin, McKelvey et al. 2006). Note that relative adduct concentrations, which are ratios of 
the individual adduct concentrations to median adduct levels in concurrent controls, were used to 
account for difference across control groups. With both HSA-Cys34-BO and HSA-Cys34-1,4-BQ, 
a clear dose-response is observed.  
 
 
Figure 1.3.  HSA-Cys34 adducts of benzene oxide (BO) and 1,4-benzoquinone (1,4-BQ), 
versus personal benzene exposure for 439 Chinese workers. (Figure from Rappaport et. al. 
The Use of Newborn Blood Spots in Environmental Research: Opportunities and 
Challenges Meeting, Chapel Hill, NC, Feb 20, 2007) 
 
 
 
The utility of HSA cysteinyl adducts as exposure biomarkers is not limited to chemical 
mutagens and carcinogens. Many other classes of toxicants and/or their electrophilic metabolites 
covalently modify HSA-Cys34 (Lopachin and Decaprio 2005). In fact, it has been hypothesized 
that adduct formation with protein thiols is a critical initiating step in the mechanism of 
neurotoxic action (Graham, Amarnath et al. 1995; Lotti 2000). Consequently, HSA-Cys34-bound 
neurotoxins fall closer to health outcome within the exposure-disease continuum, and therefore 
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may provide a stronger exposure-disease relationship than those observed with chemical 
carcinogens. 
HSA-Cys34 is also modified by scavenging endogenous reactive species. Some notable 
examples are carbonylation, S-nitrosylation, and disulfide formation (Bar-Or, Heyborne et al. 
2005; Musante, Bruschi et al. 2006; Musante, Candiano et al. 2007; Perna, Acanfora et al. 2007). 
Disulfide adducts can undergo further oxidation to form sulfenic, sulfinic, and sulfonic 
derivatives (Aldini, Regazzoni et al. 2008). All these modifications have been employed as 
biomarkers of associated physiopatholgical conditions, including oxidative stress, renal disease, 
growth restriction, and glomerulosclerosis (Aldini, Regazzoni et al. 2008). Given the profusion 
of chemical species that modify HSA-Cys34, this reactive nucleophilic target is clearly a 
promising site for surveying modifications as potential biomarkers.  
 
 
1.5. Specific goals  
The primary aim of this study is to extend the use of protein adducts as exposure 
biomarkers to epidemiological research. Towards this end, the following specific goals are given: 
 
Goal 1: Develop a method to measure protein adducts in DBS. This goal will (1) permit direct 
measurement of prenatal exposures to chemical toxicants using archived newborn DBS, and (2) 
will provide a less invasive and less expensive blood collection procedure to make protein 
adducts assays more applicable to population-based studies. As proof-of-concept that protein 
adducts can be measured in DBS, benzene oxide adducts of Hb will be measured and compared 
between newborns and adults. Method validation will be achieved by comparing adult DBS to 
matching specimens isolated from venous whole blood (Paper 1). 
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Goal 2: Develop a method to enrich cysteinyl adducts of HSA. The enrichment approach will 
utilize the propensity of free sulfhydryls in HSA to bind with thiol-affinity resins. HSA will first 
be reduced to liberate Cys34 bound mixed disulfides, and mercaptalbumin will be subsequently 
removed using thiol-affinity covalent chromatography. Mass spectra will be acquired for intact 
HSA to assess optimal reduction conditions and the effectiveness of the enrichment procedure. 
Overall adduct levels will be estimated by measurement of total proteins after enrichment, i.e. 
after removal of mercaptalbumin, using the Bradford assay and gel electrophoresis (Paper 2)
 
 
2. Development of a Method to Measure Protein Adducts in Dried Blood Spots 
 
 The goal of this work is to develop a method to measure protein adducts in DBS. The 
DBS sampling medium offers several advantages over conventional venous blood specimens, 
including less invasive blood collection, simplified specimen processing and shipment, and most 
notably, an opportunity to access archived neonatal blood samples which are stored as residual 
Guthrie cards.  
 
 
2.1 Isolation of proteins from dried blood spots 
 
2.1.1. Precipitation of proteins using addition of acetone 
 
Obtaining sufficient protein is a major challenge when developing an assay for protein 
adducts in DBS. This challenge arises from (1) the limited mass of protein contained within a 
single drop of blood, and (2) the complexity of the whole blood matrix. Given the limited blood 
volume present in a DBS, high protein recovery is required when isolating proteins for 
measuring protein adducts. In addition, to be useful for large-scale epidemiological studies, the 
isolation protocol should be relatively simple and inexpensive. To address these criteria a method 
was explored to isolate Hb and HSA from DBS using a cosolvency approach.  
Many factors affect a protein’s solubility. One important parameter is the dielectric 
constant of the solvent. Polar solvents, such as water, have high dielectric constants. In contrast, 
organic solvents have relatively low dielectric constants, and often result in protein precipitation 
(Chin, Wheeler et al. 1994). When two miscible solvents are combined, the resulting dielectric 
constant is intermediate to those of the individual solvents. Consequently, the dielectric constant 
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of a mixture can be controlled by the relative ratios of solvents. Proteins in a mixture can 
then be separated by identifying the solvent combinations that selectively precipitate individual 
proteins.  
Cosolvency experiments were conducted using mixtures of acetone and water. Solvent 
conditions were explored to separate Hb from HSA because the two proteins make up over 90% 
of total blood proteins. Initial experiments were conducted using purified Hb and HSA (Sigma-
Aldrich, St. Louis, MO) to determine the approximate solvent ratios where each protein 
precipitated individually. Based on these crude results, twenty solutions were prepared with 
increasing percentages of acetone, ranging in dielectric constant from approximately 48 to 24. 
Blood was spotted onto specimen collection cards from a single volunteer via finger lancet and 
was dried overnight. Single DBS were excised and extracted using 4 ml of deionized water. 
Extracted blood samples were then concentrated using a speed vacuum system to approximately 
200 µl. The concentrated blood samples were added drop-wise to the different solvent mixtures. 
All protein solutions were incubated for 3 hours at 4°C. Vials were centrifuged at 2,200 x g for 
15 minutes to pellet any precipitated proteins and to allow the removal via Pasteur pipet of the 
supernatant fractions for analysis. The soluble protein fractions were analyzed using UV/vis 
spectrophotometery, monitoring absorbance at 280 and 523 nm. Solvent blanks were used to 
subtract out the absorbance due to acetone. Absorbance at 280 nm was used to estimate total 
protein, whereas absorbance at 523 nm was used for more specific detection of oxyhemoglobin 
and deoxyhemoglobin. Total protein concentrations were confirmed using the Bradford. Results 
are shown in Figure 2.1. 
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Figure 2.1.  DBS protein precipitation using addition of acetone. The upper panel shows 
UV/vis absorbance for proteins eluted from DBS using various acetone concentrations. 
Absorbance at 523 nm was used to monitor Hb precipitation, and absorbance at 280 nm 
was used to track total DBS protein solubility. In the lower panel, the Bradford assay was 
used for total protein quantitation. 
 
The results in the upper panel of Figure 2.1 were in agreement with the cursory results 
obtained using isolated Hb and HSA. When examined as single proteins, Hb precipitated when 
the dielectric constant fell below approximately 40. In contrast, HSA remained soluble until the 
dielectric constant reached values below approximately 28. Monitoring absorbance at 280 nm, 
proteins extracted from DBS appeared to precipitate at dielectric constants between 40 and 42, 
with an increase in precipitation around 28. While such results suggest that the strategy was 
separating Hb from HSA, results from the more specific Bradford assay indicated that the vast 
majority of the protein precipitated with a dielectric constant of about 40, suggesting that HSA in 
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the crude mixture precipitated at substantially higher dielectric constants than when present 
alone. 
It was later confirmed, that the presence of Hb altered HSA's solubility. The non-protein 
substance that absorbed at 280 nm was present in the supernatant when Hb was precipitated as a 
single protein. When Hb was removed, and HSA was placed in the Hb supernatant, HSA 
precipitated under solvent conditions that would otherwise solubilize HSA. This change in 
solubility may be due to formation of a bilirubin-HSA complex. Bilirubin is formed during 
hemoglobin decomposition, and is know to bind with HSA with very high affinity (Vlasova, 
Golovkova et al. 2005). Further studies are required to test this hypothesis.  
2.1.2. Isolation of Hb in DBS using addition of ethanol 
A method to isolate Hb from DBS was developed using ethanol/water cosolvency. The 
method was developed using a similar approach to the one described above using acetone/water 
mixtures. The use of ethanol as a solvent was chosen based on a previous study by Tanaka et al. 
who used an ethanol/water/chloroform mixture to purify bovine serum albumin that was 
contaminated with Hb (Tanaka, Sawatani et al. 2001).  
Various solvent parameters were investigated using ethanol concentrations ranging from 
10 to 65 percent. The experiment was performed twice, with and without 0.6% chloroform. 
Absorbance was measured at 523 nm to monitor the Hb concentration, and the Bradford assay 
was used to determine total protein in each sample (Figure 2.2.).  
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Although chloroform was observed to shift the solubility of both Hb and HSA, it was 
excluded from the final protocol because chloroform did not provide any advantage in separating 
Hb from HSA. In contrast with acetone, the addition of ethanol did not cause HSA to co-
precipitate with Hb. Based on experiments performed with single proteins, and with total DBS 
proteins, 43% ethanol was determined to be the optimal concentration to precipitate Hb while 
retaining HSA in solution.  
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Figure 2.2.  DBS precipitation of proteins by addition of ethanol. Total protein 
precipitation occurred at approximately 21 and 35 percent ethanol, with and without 
chloroform addition, respectively. HSA precipitated at approximately 61 and 65 
percent ethanol, with and without the addition of chloroform, respectively. The range 
in between these percentages represents conditions where HSA is soluble, and Hb is 
not. 
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2.1.3. Isolation of globin from Hb 
After the Hb was isolated from the DBS, a second precipitation step was preformed using 
acidic acetone at -20°C. This procedure denatures the Hb and separates the globin (Gb) fraction 
of the protein from the heme fraction via precipitation of the Gb. Details of this procedure are 
outlined in Section 3.3.4. A schematic of the entire DBS Gb isolation method is shown in Figure 
2.3. 
                          
Figure 2.3.  A schematic of the DBS Gb isolation method, with two-dimensional 
electrophoresis gel images comparing the purity of the isolated Gb to our conventional 
venous blood protocol. 
 
2.1.4. Assessment of Gb purity 
 To determine the purity of the Gb isolated from DBS, two-dimensional gel 
electrophoresis was performed using the carrier ampholine method of isoelectric focusing 
(Kendrick Labs, Madison WI). A detailed description of the procedure is provided in Section 
3.3.5.  Gel images of the isolated Gb are shown in Figure 2.3. A 2D-gel image of the supernatant 
fraction is shown in Figure 2.4, which is primarily HSA. 
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Figure 2.4.  Two-dimensional gel electrophoresis image of the supernatant fraction after 
Hb precipitation. 
  
The purity of the isolated globin, assessed by two dimensional gel electrophoresis, was 
determined by laser densitometry to be ~96%. The purity of HSA in the supernatant fraction was 
46.6%. Because HSA represents 12% of the total protein in whole blood, this indicates that HSA 
was substantially purified in the supernatant fraction, although the supernatant still contained 
other blood proteins (~34.6% from Hb). The percentage of ethanol could be increased during the 
cosolvency precipitation to achieve greater HSA purity, but this would be at the expense of 
reducing the purity of Hb. 
2.1.5. Qunatitiation of isolated Gb from adult and newborn DBS 
Gb was isolated from 50 adult DBS and 52 newborn DBS using the procedures detailed 
in sections 2.1.2 and 2.1.3, for precipitation of Hb and Gb, respectively. The adult DBS were 
prepared using archived venous blood that was previously stored at -80°C. Each adult DBS was 
prepared using 50 µl aliquots of whole blood. The newborn DBS came from heel sticks and were 
received within 30 days of blood collection from the North Carolina Laboratory of Public Health 
(Raleigh, NC). Each newborn DBS consisted of a single spot excised from the specimen 
HSA
Gb
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collection cards which was then individually sealed in a plastic bag and stored at room 
temperature until extracted. Globin mass isolated for each DBS specimen was determined using 
the Bradford method.  
The mean Gb isolated from adult and newborn DBS was 5.0 mg (SD = 0.9) and 9.4 mg 
(SD = 2.4), respectively. These results are consistent with data from previous studies, in which 
newborns had higher Hb concentrations than adults (Kates and Kates 2007).  
The mass of Gb required for protein adduct assays is less than 5 mg of isolated protein 
(Waidyanatha, Yeowell-O'Connell et al. 1998; Rappaport, Waidyanatha et al. 2002). Based on 
the mass of Gb isolated from the newborn and adult DBS, and given the relatively high purity of 
the protein (determined via two-dimensional gel electrophoresis), DBS appear to be a suitable 
medium for obtaining blood specimens for assaying Hb adducts. 
                       
2.2 1,4-benzoquinone adducts in dried blood spots 
2.2.1. 1,4-benzoquinone adducts of Hb in adult and newborn DBS 
As proof-of-concept that protein adducts can be measured in DBS, 1,4-benzoquinone 
adducts of Gb (1,4-BQ-Gb) were measured in 50 adult and 51 newborn DBS specimens. A 
method to measure mono-S-substituted cysteinyl adducts of 1,4-benzoquinone (1,4-BQ) was 
developed in our laboratory and is described in detail elsewhere (Waidyanatha, Yeowell-
O'Connell et al. 1998). In short, 3 mg of Gb was spiked with 5 μg of isotopically labeled internal 
standard ([2H3]1,4-BQ-Gb). Ascorbic acid was added to reduce 1,4-BQ adducts to hydroquinone, 
and trifluoroacetic anhydride and methanesulfonic acid were reacted with the protein to cleave 
cysteinyl protein adducts and convert them to volatile trifluorothioacetates. The derivatized 
analytes were solvent exchanged into hexane and were concentrated to a final volume of 
27 
 
approximately 200 μl under a gentle stream of nitrogen. Quantitative analysis was performed 
using GC/MS in chemical ionization-negative ion mode.  
Levels of 1,4-BQ-Gb quantified in the 51 newborn and 50 adult DBS are shown in Figure 
2.5. The estimated mean level of 1,4-BQ-Gb in the newborn and adult DBS was 3.93 pmol/mg 
Gb (SD 1.41) and 1.84 pmol/mg Gb (SD 0.63), respectively. Estimated adduct levels were not 
assumed to be distributed normally and were compared between groups using the nonparametric 
Wilcoxon rank-sum test. 1,4-BQ-Gb levels were significantly different between the two groups 
(p < 0.005), with newborn DBS having approximately two times higher adduct levels than adult 
DBS.  
                    
 
        
With our conventional Gb isolation procedure (isolated from venous blood), Hb samples 
are dialyzed against deionized water prior to Gb precipitation. This step is not included in the 
DBS Gb isolation protocol because smaller soluble compounds are likely to be removed when 
the Hb is precipitated, and the supernatant is decanted. However, a possible explanation for the 
elevated adduct levels observed in the newborn population could be that additional adducts are 
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            Figure 2.5.  1,4-BQ-Gb levels in newborn and adult DBS. 
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formed with small thiol sources, such as glutathione. These may be present in the DBS samples 
since the DBS protocol did not include a dialysis step. This hypothesis is tested in Section 2.2.2. 
 2.2.2. Reassessment of 1,4-BQ-Gb following dialysis 
Globin isolated from 48 newborn and 22 adult DBS was dialyzed to remove any quinone-
adducted small thiols. Aqueous Gb samples were transferred to 12-14 KDa molecular weight cut 
off (MWCO) dialysis tubing and were dialyzed against 4 liters of deionized water at 4°C. The 
water bath was changed 3 times during the 12 hour-hour assay. Dialyzed Gb was transferred to 
pre-weighed 4 ml glass vials and was dried using a speed vacuum system and weighed. Three 
mg portions of Gb were re-assayed for 1,4-BQ-Gb using the MT assay described above. 
The mean level of 1,4-BQ-Gb in the newborn DBS was 1.39 pmol/mg Gb (SD 0.60) and 
the mean level of 1,4-BQ-Gb in the adult DBS was 0.68 pmol/mg Gb (SD 0.15). These results 
are summarized in Figure 2.6 and are compared to those from the undialyzed specimens. As 
before, adduct concentrations were compared between groups using the nonparametric Wilcoxon 
rank-sum test. Consistent with undialyzed Gb adduct levels, 1,4-BQ-Gb was approximately two 
times higher in the newborn DBS samples. The mean adduct levels were significantly different 
between the two populations (p < 0.05). Interestingly however, adducts levels were significantly 
lower in both post-dialyzed groups. This result was surprising, given that the adult Gb had 
previously been dialyzed.  
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2.2.3. Reaction of newborn and adult Gb with 1,4-BQ 
 Newborn DBS had consistently higher 1,4-BQ-Gb concentrations than the adult DBS for 
both the dialyzed and undialyzed Gb specimens. A possible explanation for the elevated adduct 
levels in the newborn DBS is that 65-85% of newborn Hb is comprised of the HbF variant, 
whereas the dominant Hb variant in adults is HbA (Cochran-Black, Cowan et al. 2001). Both 
protein variants contain four subunits; however, HbA has two α-subunits and two β-subunits, 
whereas the HbF contains two α-subunits and two γ-subunits. In both the β- and γ-subunits Cys93 
is conserved, and is the site of 1,4-BQ modification. However, in the γ-subunit His143 is replaced 
with Ser143. This amino acid substitution impedes 2,3-bisphosphoglycerate binding in the HbF 
variant. Because 2,3-bisphosphoglycerate is a competitive inhibitor of oxygen binding,  this 
change results in higher oxygen affinity in fetal blood compared to adults (Orzalesi and Hay 
1972). Due to the close proximity of His143γ and Cys93γ (Figure 2.7), we hypothesize that this 
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Figure 2.6.  1,4-BQ-Gb levels in newborn and adult DBS, before and after dialysis. 
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amino acid substitution could also cause structural changes that may provide better access to 
Cys93γ in the fetal variant, thus increasing Cys93 activity. If so, such a mechanism could act as a 
defensive mechanism to scavenge reactive electrophilic species more efficiently during fetal 
development. 
 
               
Figure 2.7.  Three dimensional space-filling structures of the adult and fetal        variants of 
Hb, showing the greater accessibility of Cys93 in the HbF variant. 
(http://www.rcsb.org/pdb/home/home.do) 
 
 
 To test whether the HbF variant was more reactive than the HbA variant, blood was 
obtained from a single newborn and the mother at birth. Hb was isolated from the blood and the 
proteins were reacted with 1,4-BQ. Whole umbilical cord and matching maternal blood collected 
by venipuncture were obtained from UNC Hospitals. The umbilical cord blood (42 ml) was 
collected at birth, placed in citrate, stored a 4ºC until received by our lab 13 hours later. The 
maternal blood (14 ml) was collected one hour prior to receipt by our lab. 
 Both specimens were immediately centrifuged at 2,200 x g for 15 minutes. The upper 
plasma layer, containing HSA, was removed by Pasteur pipet. The red blood cell fraction was 
HbA HbF
Cys93
His143
Ser143
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washed three times with 0.9% sodium chloride solution. The plasma and red blood cell fractions 
were divided; half the specimens were frozen at -20˚C and half were stored overnight at 4˚C. 
 The red blood cells were diluted with an equal volume of deionized water and stored at 
4˚C overnight to lyse the red blood cells. The lysate was centrifuged at 30,000 x g for 45 minutes 
at 4˚C to pellet the cell membranes. The supernatant fractions were decanted and dialyzed using 
6-8 KDa MWCO dialysis tubing overnight, with 3 changes of water (4 liters each). Hemoglobin 
concentrations were determined in each of the samples using the Bradford assay. Concentrations 
of the maternal Hb and fetal Hb were determined to be 111.3 mg/ml and 107.5 mg/ml, 
respectively. 
One μM 1,4-BQ was reacted with the maternal and fetal Hb, using a 221-fold molar 
excess of Hb. Because newborn and maternal blood share a common HSA variant, maternal and 
fetal HSA were also reacted with 1,4-BQ to serve as positive controls. The reactions proceeded 
for 1 hour at 37°C. Based on previous 1,4-BQ kinetic experiments performed in our laboratory, 
the reactions were assumed to have gone to completion. The solutions were dried using a speed 
vacuum system. One mg aliquots of HSA and 3 mg aliquots of Hb were assayed in duplicate for 
1,4-BQ cysteinyl adducts using the MT assay (Section 2.2.1.).  
 Mass spectrometry response ratios, relative to the isotopically labeled internal standards, 
are provided in Table 2.1. Relative responses were compared across groups to assess if the HbF 
variant was more reactive than the HbA adult variant. To account for differences observed with 
the adult and newborn DBS, the HbF variant would need to be approximately twice as reactive 
as the HbA variant to be detected.                     
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Table 2.1.  Reaction of adult and fetal Hb variants with 1,4-BQ. Results are provided as 
NCI-GC/MS relative ion response ratios between the analytes and the internal standards.                                    
     
 
 
1,4-BQ adduct levels, before and after reaction with 1,4-BQ, are displayed in Figure 2.8, 
with standard deviations noted within each group. These results include Hb and HSA from both 
cord blood and matching maternal blood specimens. HSA was significantly more reactive than 
Hb in both the fetal and maternal samples. As a result, 1,4-BQ-HSA concentrations are plotted as 
natural logarithms. Although statistical conclusions are limited given the extremely small sample 
size, the reactivity of the two Hb variants do not appear to be sufficiently different to explain the 
differences observed previously between the newborn and adult DBS.  
 
Reaction status Sample ID Protein 
mass (mg)
Relative response 
(RR) 
RR/protein mass 
Unreacted Maternal HSA 1 0.108 0.108
Maternal HSA 1 0.109 0.109 
Fetal HSA 1 0.073 0.073 
Fetal HSA 1 0.092 0.092 
Reacted with 1,4-BQ Maternal HSA 1 20.86 20.86 
Maternal HSA 1 22.49 22.49 
Fetal HSA 1 16.02 16.02 
Fetal HSA 1 15.09 15.09 
Unreacted Maternal Hb 3 0.321 0.107 
Maternal Hb 3 0.272 0.091 
Fetal Hb 3 0.303 0.101 
Fetal Hb 3 0.310 0.103 
Reacted with 1,4-BQ Maternal Hb 3 0.678 0.226 
Maternal Hb 3 0.745 0.249 
Fetal Hb 3 0.768 0.256 
Fetal Hb 3 0.912 0.304 
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Figure 2.8.  Measurement of 1,4-BQ adducts of fetal and adult blood proteins before and 
after reaction with 1,4-BQ. 
 
2.2.4. Assessment of the stability of 1,4-BQ-Gb in DBS stored at room 
temperature for up to 1 year 
 The stability of 1,4-BQ-Gb in DBS was assessed in DBS stored at room temperature for 
up to one year. Fresh blood was collected from an adult volunteer by venipuncture in heparin 
vacutainer tubes. The blood was immediately applied to specimen collection paper in 60 μl 
aliquots. At time intervals of 0, 0.5, 1, 3, 6, and 12 months, DBS were excised and extracted in 2 
ml of deionized water using increasing numbers of DBS (3 DBS for times 0, 0.5, and 1 month; 4 
DBS for times 3 and 6 months; and 6 DBS for the specimens stored for 12 months) to recover 
adequate protein for adduct measurement. The samples were agitated at 160 rpm for 90 minutes 
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and the specimen collection paper was removed using forceps. All samples were stored at -80˚C 
until assayed for 1,4-BQ-Gb. 
 The efficiency of recovering proteins from DBS stored at room temperature significantly 
declined after 6 months of storage (Figure 2.9). This effect may have been exacerbated by 
heparin which had been used as an anticoagulant in the blood used to prepare the DBS. Dried 
blood spots collected by finger lancet and stored at room temperature were extracted after 
storage for 7 to 10 months. A significant decline was also observed in these samples, though the 
effects appeared less extreme than for DBS prepared from the blood containing heparin. This 
observation is encouraging because aged DBS are more likely to have been collected by finger or 
heel lancet, and would therefore be devoid of blood anticoagulants such as heparin. Further 
studies are required to explore the effects of storage and protein recovery. 
 
               
Figure 2.9.  Recovery of blood proteins from DBS after extended storage                        at 
room temperature. Note that DBS specimens were pooled at each time point. 
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1,4-BQ-Gb was measured in DBS to assess the stability of these 1,4-BQ adducts during 
storage (Figure 2.10). Samples were analyzed using the MT assay at each time point using 3 mg 
of Gb. Surprisingly, adduct levels increased with greater storage times; with a significant rise in 
adduct levels between 0 and 0.5 months. Mean adult and newborn DBS 1,4-BQ-Gb levels 
(presented in section 2.3.1) are also shown for comparison with the archived samples in Figure 
2.10.  
 
        
Figure 2.10.  Stability of 1,4-BQ adducts of globin in DBS stored at room temperature for 
up to one year. 
 
 
 
All adult DBS samples from section 2.2.2. were eluted 18-36 hours after being dried on 
the specimen collection paper. In contrast, newborn DBS specimens were extracted between 7 
and 30 days after blood collection. Based on these results, adduct levels appeared to increase 
with storage time, and observed differences in adduct levels between adult and newborn DBS 
could simply point to the difference in storage time. 
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  2.2.5. Conclusions 
 A method has been developed to extract Hb from DBS using the addition of ethanol to 
selectively precipitate the Hb from the DBS whole blood matrix. This method is relatively 
simple and inexpensive, and thus is applicable to molecular epidemiological studies. Using this 
protocol, Hb can be recovered with high yield in DBS stored for up to 6 months at room 
temperature. The purity of the isolated protein was determined to be suitable for protein adduct 
assays. 
 1,4-BQ adducts of Gb in DBS significantly increased when stored at room temperature. 
Reasons for the increase in adducts during storage may be related to quinone-specific redox 
properties. Further investigations are required to explore this phenomenon.  
 
                  
Figure 2.11.  Schematic of the metabolism of benzene, highlighting the reactive metabolites 
BO and 1,4-BQ 
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To demonstrate that proteins can be isolated from DBS and used in protein adduct assays 
as exposure biomarkers, an alternative adduct, benzene oxide (BO), was selected for monitoring. 
Like 1,4-BQ, BO is a reactive metabolite  of benzene (Figure 2.11), and its adducts have been 
detected in both Hb and HSA (Rappaport, McDonald et al. 1996; Yeowell-O'Connell, McDonald 
et al. 1996; Troester, Lindstrom et al. 2000). Exposure to benzene is among the few established 
environmental causes of leukemia in adults (Savitz and Andrews 1996; Sonawane, Bayliss et al. 
2000; Vermeulen, Li et al. 2004). The mechanism by which benzene and its reactive 
intermediates induce leukemia is not fully understood. However, BO, benzoquinones, and 
muconaldehydes are all electrophilic metabolites of benzene that modify DNA and proteins, and 
are suspected to play a causal role in benzene-induced leukemia (Sonawane, Bayliss et al. 2000). 
A method for measuring BO cysteinyl adducts of Gb in DBS is presented in Section 3.
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3. Paper I.  Hemoglobin adducts of benzene oxide in neonatal and adult dried blood 
spots [Funk, W.E., Waidyanatha, S., Chaing, S.H., Rappaport, S.M. (2008) Cancer 
Epidemiology Biomarkers and Prevention, 17(8) 1896-1901] 
 
 
 3.1. Abstract 
 
Adducts of reactive chemicals with Hb or HSA can be used as biomarkers of internal 
doses of carcinogens. Because dried blood spots are easier to collect and store than conventional 
venous blood samples, they encourage applications of biomarkers of exposure in large 
epidemiologic studies. In addition, neonatal dried blood spot can be used to investigate chemical 
exposures in utero. Here, we report a simple method to isolate Hb from dried blood spot with 
high recovery and purity using the addition of ethanol to aqueous dried blood spot extracts. To 
prove the concept that dried blood spot–derived proteins can be used to assay for adducts, we 
measured Hb adducts of benzene oxide, a reactive metabolite of the ubiquitous air pollutant 
benzene in nine neonatal and nine adult dried blood spots (from volunteer subjects), using a gas 
chromatography–mass spectrometry method that we had previously developed. For comparison, 
benzene oxide–Hb adducts were measured in the same nine adult subjects using Hb that had 
been isolated and purified using our conventional method for venous blood. The geometric mean 
of benzene oxide–Hb levels in all dried blood spot samples ranged from 27.7 to 33.1 pmol/g 
globin. Neither of the comparisons of mean (logged) benzene oxide–Hb levels between sources 
(adult conventional versus adult dried blood spot and adult dried blood spot versus newborn 
dried blood spot) showed a significant difference. Based upon the estimated variance of the 
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benzene oxide–Hb levels, we had 80% power to detect a 1.7-fold difference in geometric 
mean levels of benzene oxide–Hb in our sample of nine subjects. 
 
 
3.2. Introduction 
Biomarkers of internal dose can be more accurate and precise surrogates for carcinogen 
exposures than environmental measurements per se (Lin, Kupper et al. 2005). However, because 
chemical carcinogens are usually reactive electrophiles with very short life spans in vivo (e.g., 
alkylating and acylating agents, aldehydes, alkylnitrosamines, dialkylsulfates, oxiranes, 
quinones, reactive oxygen, and nitrogen species; (Miller and Miller 1966), it is rarely possible to 
measure them in target tissues. This has motivated the use of adducts of these electrophiles with 
abundant blood proteins, particularly Hb and HSA, as measures of carcinogen dose (Groth and 
Neumann 1972; Ehrenberg, Hiesche et al. 1974). Electrophiles enter the blood from absorption 
in the lungs or gut (e.g., inhalation of ethylene oxide) or, more typically, via the metabolism of 
procarcinogens in the liver or other tissues (e.g., production of benzene oxide by cytochrome 
P450 metabolism of benzene). Once in the blood, electrophiles react at varying rates with all 
available nucleophiles to form adducts by numerous mechanisms (Tornqvist, Fred et al. 2002). 
Hb and human serum albumin contain a myriad of nucleophilic sites, namely the free thiol 
groups of Cys; amine groups of His, Trp, Lys, and the N-termini; hydroxyl groups of Ser and 
Tyr; and the carboxylic acid groups of Asp, Glu, and the C-termini. Because protein adducts are 
not repaired and are much more abundant than DNA adducts in blood (1 ml of blood contains 
about 150 mg Hb, 30 mg of human serum albumin, and 0.003-0.008 mg of DNA; (Tornqvist, 
Fred et al. 2002)), they are potentially more useful measures of internal dose than DNA adducts, 
which have paradoxically received far more attention in this regard. Indeed, the kinetics of 
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production and elimination of Hb and human serum albumin adducts are sufficiently simple to 
permit straightforward estimates of systemic doses of carcinogens over the mean residence time 
of these proteins (28 days for human serum albumin and 63 days for Hb in humans; (Ehrenberg, 
Moustacchi et al. 1983; Granath, Ehrenberg et al. 1992; Rappaport, Waidyanatha et al. 2002)). 
Levels of targeted Hb and/or human serum albumin adducts have been investigated in 
human blood for several environmental toxicants that are either electrophilic carcinogens or their 
precursors, that is, ethylene oxide, benzene, 1,3-butadiene, acrylamide, aflatoxin B1, a variety of 
aromatic amines, and polycyclic aromatic hydrocarbons (reviewed in (Tornqvist, Fred et al. 
2002)). However, the need to obtain venous blood samples has limited the utility of protein 
adducts (and other blood-based biomarkers) as measures of exposure in large epidemiologic 
studies. This has motivated investigators to use dried blood spots that can be obtained by a 
simple skin prick as sources of blood biomarkers. Guthrie and Susi (Guthrie and Susi 1963) first 
used dried blood spots in the 1960s to screen newborn populations for hyperphenylalanine 
associated with the genetic disease phenylketonuria. Neonatal dried blood spots offer valuable 
opportunities for investigating chemical exposures in utero and their possible links to childhood 
cancers. Immunoassays have been applied to measure a variety of biomarkers in dried blood 
spots from adult populations, for example, folate (O'Broin and Gunter 1999), transferrin receptor 
(McDade and Shell-Duncan 2002; Shell-Duncan and McDade 2004), immunoglobulin E (Tanner 
and McDade 2007), Epstein-Barr virus antibodies (McDade, Stallings et al. 2000), leptin (Miller, 
Sharrock et al. 2006), and C-reactive protein (McDade, Burhop et al. 2004). Thus, dried blood 
spots can potentially be used in both prospective and retrospective studies to process large 
numbers of blood specimens from human subjects.  
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A single dried blood spot contains about 50 µL of human blood (O'Broin and Gunter 
1999). Assuming a protein concentration of 192mg/mL (Longe and Blanchfield 2002), one dried 
blood spot should contain about 9.6 mg of protein, of which there should be about 7.7 mg of Hb 
(80% of total protein) and 1.2mg human serum albumin (12% of total protein). Because most 
current assays for protein adducts typically require between 1 and 10 mg of globin (from Hb) or 
human serum albumin, a single dried blood spot should contain sufficient quantities of these 
proteins to measure adducts. Here, we describe experiments to isolate Hb in high purity from a 
single dried blood spot, to purify the resulting globin, and to measure cysteinyl adducts of 
benzene oxide (benzene oxide–Hb) in these proteins. We previously detected benzene oxide–Hb 
in globin isolated from conventional venous blood samples in both benzene-exposed and control 
subjects and showed that levels of benzene oxide–Hb increased with the level of benzene 
exposure (Yeowell-O'Connell, Rothman et al. 2001). Detection of benzene oxide– Hb in control 
subjects points to production of adducts from environmental exposures to benzene and/or dietary 
and endogenous sources of benzene oxide or other precursor molecules that produce the same 
adduct (Yeowell-O'Connell, Rothman et al. 1998). In the current study, we show that benzene 
oxide– Hb is present at comparable levels in adult globin, isolated either from dried blood spots 
or from conventional RBCs, and in globin obtained from neonatal dried blood spots. 
 
3.3. Methods and Methods 
3.3.1. Chemicals 
S-phenylcysteine and [2H5]S-phenylcysteine were kindly provided by Dr. A. Gold of the 
Chemistry Core of the Superfund Basic Research Program at the University of North Carolina, 
Chapel Hill. Hydrochloric acid (concentrated), acetone (nanograde), hexanes 
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(pesticide grade), and ethanol (100%) were purchased from Fisher Scientific. Methanesulfonic 
acid was obtained from Fluka Chemical Company. Trifluoroaceticanhydride was from Pierce 
and was distilled once before use. Human Hb was purchased from Sigma Chemical Company. 
ProteinSaver 903 specimen collection cards were purchased from Whatman. Safety lancets for 
preparation of fresh adult dried blood spots were obtained from Fisher Scientific. Bio-Rad 
protein assay reagents were purchased from Bio-Rad Laboratories. 
3.3.2. Dried blood spots 
 
Nine newborn dried blood spots, collected via heel lancet, were obtained from the North 
Carolina Laboratory of Public Health. These single dried blood spots, which were collected on 
Whatman ProteinSaver 903 specimen collection cards, were obtained within 30 days of 
collection. Nine adult dried blood spots were prepared using archived frozen whole blood, 
randomly selected from 191 adult volunteer subjects collected in the state of North Carolina in 
1998 and stored at -80ºC (Lin, McKelvey et al. 2006). After thawing to room temperature, 50 µL 
aliquots of these blood specimens were spotted on specimen collection cards to produce adult 
dried blood spot; these dried blood spots were stored at room temperature for 2 weeks before 
processing. Five of the nine adult dried blood spots were spotted in duplicate to assess assay 
precision. Fresh adult dried blood spots, required for experiments to develop the method, were 
prepared on specimen collection cards with blood obtained by finger lancet from laboratory 
volunteer subjects. 
3.3.3. Precipitation of Hb via addition of ethanol 
To determine optimal conditions for precipitating Hb, while leaving other blood proteins 
in solution, dried blood spot specimens were precipitated from varying mixtures of ethanol or 
water. Eighteen individual dried blood spots from a single volunteer subject were dried overnight 
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and then excised with scissors and extracted with 2 ml of deionized water by agitation on a 
shaker table (Lab-Line 4626, Barnstead) at 160 rpm for 90 min. The specimen collection paper 
was removed using forceps, and the eluted blood was concentrated to ~200 µL using a speed 
vacuum system (Savant SC110, ThermoFisher Scientific). To determine the optimum 
concentration of ethanol or water to precipitate Hb, the eluted blood was added Drop-wise to 
aqueous solutions containing between 15% and 66% ethanol in increments of 3% ethanol. All 
samples were incubated at 4ºC for 1 h and were centrifuged at 30,000 x g to pellet the 
precipitated protein. The supernatant fraction, containing soluble proteins, was decanted and 
discarded. Total protein concentration was measured in the precipitated protein fraction using a 
variation of the Bradford assay (Bio-Rad Protein Assay, Bio-Rad Laboratories) based upon 
absorbance at 595 nm. Hb concentrations were estimated by selective absorbance at 523 nm. 
3.3.4. Isolation of globin from dried blood spots and RBCs 
 
Dried blood spots were excised from specimen collection cards with scissors and placed 
in 4-mL glass vials with Teflon-lined caps. Deionized water (2 ml) was added, and the vials were 
briefly agitated with a vortex mixer and then gently mixed on a rotary shaker (Lab- Line 4626, 
Barnstead) at 160 rpm for 90 min. The specimen collection paper was removed with forceps, and 
the eluted blood was dried with a speed vacuum system. After dissolving the dried proteins in 
570 µL of deionized water, 430 µL of ethanol (43% v/v, which was found to be optimal in the 
preliminary experiment described above) was added drop-wise to selectively precipitate Hb. 
Samples were incubated at 4°C for 1 h, transferred to 1.5-mL plastic vials, and centrifuged at 
30,000 x g to pellet the Hb. The precipitated Hb was reconstituted in 200 µl of deionized water 
and then added drop-wise to preweighed 4-ml glass vials containing 2 ml of 0.1% HCl in acetone 
(20ºC) to precipitate globin. Vials were incubated for 4 h at 20ºC, centrifuged, and the 
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supernatant was decanted. The globin was then washed thrice with ice-cold acetone and was 
dried in a vacuum oven overnight at 37ºC and 15 mmol/l Hg. The amount of isolated globin was 
determined gravimetrically. 
Globin had been isolated from RBCs from the same nine subjects who provided dried 
blood spots according to our conventional method (Yeowell-O'Connell, McDonald et al. 1996). 
Portions of these conventional globin specimens were processed in parallel with globin derived 
from dried blood spots. 
3.3.5.  Analysis of globin purity from dried blood spots 
Two-dimensional electrophoresis was done using the carrier ampholine method of 
isoelectric focusing by Kendrick Laboratories. Nonequilibrium pH gradient electrophoresis was 
carried out in a glass tube with an inner diameter of 2.0 mm at 200 V for 13 h using 
1.5% (pH 3.5-10) and 0.25% (pH 8 to 10.5) ampholines (GE Healthcare). Tropomyosin (1 Ag; 
molecular weight, 33,000; pI 5.2) and 1 Ag of lysozyme (molecular weight, 14,000; pI 11.5) 
were added as internal markers. After equilibrium in SDS sample buffer (10% glycerol; 
50 mmol/l dichlorodiphenyltrichloroethane; 2.3% SDS; 0.0625 mol/L Tris; pH 6.8), each tube 
gel was sealed to the top of a stacking gel overlying a 12% acrylamide slab gel (0.75 mmol/l 
thick), and SDS slab gel electrophoresis was carried out for 4 h at 15 mA per gel. The following 
proteins were added as molecular weight standards: myosin (molecular weight, 220,000), 
phosphorylase A (molecular weight, 94,000), catalase (molecular weight, 60,000), actin 
(molecular weight, 43,000) carbonic anhydrase (molecular weight, 29,000), and lysozyme 
(molecular weight, 14,000; Sigma Chemical Co). Gels were scanned with a laser densitometer 
(model PDSI, Molecular Dynamics Inc.), which had been checked for linearity with a calibrated 
neutral density filter set (Melles Griot). The images were analyzed using Progenesis Discovery 
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software (version 2005, Nonlinear Dynamics). The general method of computerized analysis 
included automatic spot finding, background subtraction (Progenesis mathematical model), 
quantification, and matching with detailed manual checking. Purity of the globin derived from 
dried blood spot was assessed by comparing two-dimensional gels of globin from dried blood 
spot with globin derived from RBCs, assuming the latter to be 100% pure. 
3.3.6.  Analysis of benzene oxide-Hb (MT assay) 
The cysteinyl adduct of benzene oxide–Hb was assayed using the procedure of Yeowell-
O’Connell et al. (Yeowell-O'Connell, McDonald et al. 1996) with minor modifications. After 
protein isolation, 4.5 mg of globin (from either a dried blood spot or a conventional RBC 
specimen) and 1 pmol of [2H5]S-phenylcysteine (internal standard) were placed in 4-ml glass 
vials and dried in a vacuum oven (70-80ºC; 15 mmol/l Hg). Trifluoroaceticanhydride (750 µl) 
and methanesulfonic acid (20 µl) were added, and the vials were capped tightly with Teflon-
lined caps. This reaction cleaves the cysteinyl adduct of benzene oxide and converts it to the 
volatile derivative phenyltrifluorothioacetate. The reaction mixture was heated at 100ºC for 40 
min, cooled to room temperature, and the excess trifluoroaceticanhydride was removed under a 
stream of nitrogen. Hexane (1 ml) was added, and the organic extract (containing 
phenyltrifluorothioacetate) was washed with 1 ml of 0.1 mol/L Tris buffer (pH 7.3) and twice 
with 1 ml of deionized water. The hexane layer was then transferred to 1.5-ml high recovery 
autosampler vials (Agilent Technologies) and was reduced to a final volume of about 50 µl under 
nitrogen for analysis of phenyltrifluorothioacetate by gas chromatography–mass spectrometry in 
negative ion chemical ionization mode. A Hewlett Packard 5890 series II plus gas 
chromatograph and a Hewlett-Packard 5989B MS engine were used with a DB-5 fused silica 
capillary column (60 m; 0.25-mm internal diameter; 0.25-µm phase thickness; J and W 
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Scientific, Inc.) operating a helium carrier gas at a flow rate of 1 ml/min. The injection port and 
source temperatures were 250ºC and 100ºC, respectively. The oven temperature was held at 50ºC 
for 3 min and then ramped at 5ºC/min to 140ºC. Late-eluting compounds were removed by 
increasing the oven temperature to 250ºC at 50ºC/min, where it was held for 10 min. Injections 
(3 µl) were made in the splitless mode. Ions of phenyltrifluorothioacetate (m/z 206) and 
[2H5]phenyltrifluorothioacetate (m/z 211) were monitored using selective ion monitoring. To 
estimate the precision associated with the gas chromatography–mass spectrometry of the 
benzene oxide–Hb analyte, triplicate injections were done for four dried blood spots (three adult 
and one newborn), and duplicate injections were done for one adult dried blood spot. 
3.3.7.  Statistical analyses 
Adduct data were transformed to natural logarithms before statistical analyses to satisfy 
underlying assumptions about homogeneity of variance and large sample size. Sources of 
random variation of adduct levels, from errors associated with the assay and gas 
chromatography– mass spectrometry injections, were estimated using a nested random-effects 
model where injections were nested within assays and assays within dried blood spot specimens 
(Proc NESTED of SAS). The corresponding coefficients of variation (CV) were estimated as 
follows: CVassay = ሾexpሺߪො௔ଶሻ െ 1ሿ1/2 , CVinjections = ሾexpሺߪො௜ଶሻ െ 1ሿ1/2 and CVmethod = ሾexpሺߪො௔ଶ ൅
ߪො௜ଶሻ െ 1ሿ1/2, where ߪො௔ଶ and ߪො௜ଶ represent the estimated variance components (of logged data) for 
assays and injections, respectively, from the random-effects model (Yeowell-O'Connell, 
Rothman et al. 2001). Comparisons of mean (logged) adduct levels between sources of nine 
blood specimens, namely, adult conventional versus adult dried blood spot and adult dried blood 
spot versus newborn dried blood spot, used two-tailed Student’s t tests with unequal variances 
and a significance level of α = 0.05. Pearson’s correlation coefficient was estimated for (logged) 
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adduct levels from adult-conventional and adult–dried blood spot specimens. Blood specimens 
with multiple assays and/or injections were aggregated (logged levels: first by injection and then 
by assay) before testing of mean values and estimation of r. Statistical analyses used SAS 
software (version 9.1 for Windows, SAS System Software) for random-effects models and 
Microsoft Excel for t tests and correlation. 
 
3.4. Results  
3.4.1. Hb Precipitation with the addition of ethanol 
 
As shown in Fig. 3.1., Hb in blood from extracted dried blood spots began to precipitate 
at an ethanol concentration of ~20% and reached a plateau at ~37%. Human serum albumin and 
most of the other plasma proteins remained soluble until an ethanol concentration of ~47% was 
reached. Because Hb and total protein were measured using different methods (Bio-Rad assay 
for total protein and absorbance at 523 nm for Hb), and because a combination of Hb and human 
serum albumin was used as a standard in the Bio-Rad assay to approximate all of the proteins in 
blood, total precipitated protein was normalized to the Hb measurements. This adjustment was 
based on two-dimensional gel electrophoresis results (described hereafter), which showed that, 
after precipitation with 43% ethanol, Hb represented 96% of the total protein. Based on these 
results, an ethanol percentage of 43% was chosen to optimize Hb recovery from the dried blood 
spot while preventing other proteins from precipitating. 
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Figure 3.1.  Selective precipitation of Hb from dried blood spots by addition of ethanol. 
Total protein measurements were normalized to Hb levels using results from the two-
dimensional gel electrophoresis analysis, which showed that dried blood spot–derived 
globin was 96%pure when Hb was precipitated with 43%ethanol. 
 
3.4.2. Globin isolation from dried blood spots 
 
The estimated mean globins isolated from adult and newborn dried blood spots were 6.4 
mg (SD, 0.96) and 7.2mg (SD, 2.20) of globin, respectively. This corresponds to a recovery of 
>80% based on previously reported Hb levels in whole blood (adults, 140 mg/mL; newborns, 
193 mg/mL; (Kates and Kates 2007)). The purity of the isolated globin, assessed by two 
dimensional gel electrophoresis, was determined by laser densitometry to be ~96%. 
3.4.3. Precision of benzene oxide-Hb measurements in dried blood spots 
The estimated components of variance of (logged) benzene oxide–Hb levels for assays 
and gas chromatography–mass spectrometry injections were ߪො௔ଶ = 1.62 x 10-2 and 
 ߪො௜ଶ = 7.25 x 10-3. The corresponding CV values are as follows: CVassay = 0.128, CVinjection = 
0.085, and CVmethod = 0.154. Using conventional samples of globin derived from RBCs, we 
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previously reported values of CVassay = 0.28 and CVinjection = 0.10 (Yeowell-O'Connell, Rothman 
et al. 2001). 
3.4.4. Comparisons of benzene oxide-Hb levels across sources of specimens 
Table 3.1 lists the estimated means, SDs, and ranges of logged benzene oxide–Hb levels 
and the corresponding geometric mean benzene oxide–Hb levels for samples of nine globin 
specimens from different sources. The estimated statistics were very similar across sources. The 
geometric mean benzene oxide–Hb levels ranged from 27.7 to 33.1 pmol/g globin. Neither of the 
comparisons of mean (logged) benzene oxide–Hb levels between sources (adult conventional 
versus adult dried blood spot and adult dried blood spot versus newborn dried blood spot) was 
significant at α = 0.05. Figure 2 shows a scatter plot of the (logged) benzene oxide–Hb levels in 
globin derived from adult conventional RBCs and dried blood spots in single specimens of blood 
obtained from the same subjects. The Pearson r for the nine data pairs was 0.732. 
 
Table 3.1.   Summary statistics of benzene oxide-Hb levels in samples of 
globin isolated from different sources (n = 9 specimens per source) 
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3.5.      Discussion 
Although blood protein adducts of targeted electrophiles have been measured in 
humans exposed to prominent genotoxins (see review by Tornqvist et al.; (Tornqvist, Fred et 
al. 2002)), all previous investigations used venous blood samples. The purpose of this 
investigation was to prove the concept that protein adducts can be measured in dried blood 
spot-derived globin from both newborn and adult subjects. We focused upon one adduct, 
namely, benzene oxide–Hb, that we had previously measured in globin isolated from 
benzene-exposed workers and control subjects from Shanghai, China (Yeowell-O'Connell, 
Rothman et al. 2001).  
An important innovation of our assay involves the isolation of relatively pure Hb 
from a dried blood spot based upon precipitation in 43% ethanol. Conventional Hb adduct 
assays have relied on first separating RBCs (which are composed almost exclusively of Hb) 
from the plasma by centrifugation. This is not possible with dried blood spots because RBCs 
are lysed during the blood-drying process, giving rise to a more complex whole blood matrix. 
Precipitating Hb from dried blood spots via addition of ethanol provides a relatively simple 
and inexpensive means of obtaining globin for use in molecular epidemiologic studies. 
Although our focus here concerned isolation of Hb, it should be noted that, after precipitation 
of Hb, the supernatant fraction could also be used to provide additional proteins, notably 
human serum albumin.  
We successfully measured benzene oxide–Hb in all dried blood spot specimens from 
nine newborns and nine adults in North Carolina and also in globin isolated from 
conventional RBCs for the same adult subjects. No significant differences in mean (logged) 
benzene oxide–Hb concentrations were detected between samples of globin isolated from the 
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different sources (adult dried blood spot versus newborn dried blood spot and adult dried 
blood spot versus adult conventional). Because these t tests were conducted with the logged 
adduct levels, in a natural scale, they tested for differences between geometric mean benzene 
oxide–Hb concentrations in the different sources of Hb. The lack of significant differences 
between geometric mean levels indicates that the typical blood concentrations of benzene 
oxide–Hb were comparable across sources. This indicates that the typical benzene oxide– Hb 
level in adult dried blood spots was similar to that measured in conventionally isolated adult 
globin and that the typical benzene oxide–Hb level in a North Carolina newborn was similar 
to that measured in a North Carolina adult. Given a pooled estimate of the variance of 0.144 
for logged benzene oxide Hb concentrations, our tests (with nine specimens per group) had a 
power to detect a 1.7-fold difference in geometric mean values.  
Our ability to measure benzene oxide–Hb in dried blood spots proves the concept that 
a single dried blood spot provides suitable Hb for determinations of a prominent adduct in 
human populations. This conclusion is reinforced by the high pairwise correlation of benzene 
oxide–Hb levels measured in globin from dried blood spot and conventional RBCs from the 
same nine adult subjects (Fig. 3.2). Because dried blood spots can be collected much more 
simply and with greater subject acceptance than venous blood samples, this opens the door to 
the use of protein adducts as biomarkers of human exposure to benzene and to a host of 
genotoxic and carcinogenic substances in either adults or newborns. With the relentless 
improvements in analytic sensitivity that we are witnessing, it is reasonable to expect that it 
will soon be possible to conduct assays of numerous protein adducts with a small portion of a 
dried blood spot, rather than an entire dried blood spot as reported here.  
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Figure 3.2.   Scatter plot of logged levels of benzene oxide-Hb adducts measured in 
globin isolated from dried blood spots and from conventional RBCs from the same nine 
adult blood specimens (r = 0.732). 
 
 
Given the relatively long residence time of 63 days for chemically stable Hb adducts 
in human blood (Tornqvist, Fred et al. 2002), Hb adducts provide rather steady measures of 
human exposure either in utero or in adult populations. Such steady biomarkers provide less 
biasing surrogates of the true long-term exposure levels that give rise to human diseases and 
are therefore preferable to short-term biomarkers such as urinary metabolites, whose levels 
vary greatly from day to day (Rappaport and Kupper 2008).  
It is also interesting to note that the geometric mean concentration of benzene oxide–
Hb, which in our adult subjects (dried blood spot and conventional globin; n = 18) was 
e(3.32+3.50)/2 = e3.41 = 30.3 pmol/g globin, is quite similar to the median value of 37.1 pmol/g 
globin reported in 44 control subjects from Shanghai, China (Yeowell-O'Connell, Rothman 
et al. 2001). This suggests that the magnitudes of environmental, dietary, and endogenous 
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sources of the precursors of benzene oxide–Hb, which include environmental benzene and 
other (unknown) contributors, are similar indifferent parts of the world.
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4.  Development of a Method to Enrich Cysteinyl Adducts of Human Serum Albumin 
  
 In this study we report a novel method to enrich and detect cysteinyl adducts of HSA. 
The enrichment approach utilizes the propensity of free sulfhydryls in HSA to bind with thiol-
affinity resins. The majority of HSA-Cys34 in freshly isolated plasma is unmodified. 
Furthermore, within the oxidized fraction, the majority of HSA is bound reversibly with mixed 
disulfides. HSA-Cys34-mixed disulfides can be liberated via reduction with dithiothreitol (DTT), 
and mercaptalbumin can subsequently be removed using thiol-affinity covalent chromatography. 
A schematic of the enrichment approach is provided in Figure 4.1. 
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                Figure 4.1.  HSA-Cys34 adduct enrichment scheme. HSA-Cys34-SH represents 
mercaptalbumin, and HSA-Cys34-R represents a pool of irreversible Cys34 
adducts. 
 
 4.1. Initial Experiments 
  
  4.1.1. Protein-level enrichment 
 
 Five hundred mg of commercial HSA was added to 7.5 ml of 0.1 M sodium phosphate 
buffer with 0.3 M NaCl, pH 6.7. One and a half ml aliquots, each containing 100 mg of protein, 
were reacted with 25 mM DTT in phosphate buffer to liberate the Cys34 bound mixed disulfides. 
Samples were agitated at 160 rpm at room temperature for 1 hour on a shaker table, and excess 
DTT was removed by extensive dialysis against DI water.  
 Fifteen g of freeze-dried Activated Thiol Sepharose 4B was washed with 3 liters of DI 
water for 15 minutes on a sintered glass filter. A slurry was prepared using 75% settled resin to 
25% 0.1 M sodium phosphate binding buffer with 0.3 M NaCl (pH 7.4). The resin and the 
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binding buffer were degassed by bubbling in nitrogen to remove dissolved oxygen. 
Approximately 4.5 ml of resin were added to 6 ml glass columns connected to a vacuum 
manifold (Figure 4.2.). Binding buffer was added slowly under a light vacuum to pack the 
columns.   
 
 
 
 
 
 
            
     
                             
 
Figure 4.2.  Thiol-affinity covalent chromatography manifold. HSA samples are loaded 
onto the Sepharose 4B resin on top of the manifold and the enriched fraction is collected 
under light vacuum inside the manifold. 
 
Reduced HSA was added to the thiol-affinity resin. In addition, non-reduced HSA was 
added to 2 columns to assess the effectiveness of the protein reduction step. The protein solutions 
were passed drop-wise through the columns and the flow-through fractions were reloaded two 
additional times providing a one hour total residence time with the resin. The flow-through 
fractions were recovered and the columns were washed with 2-ml aliquots of binding buffer until 
absorbances at 280 and 343 nm reached baseline. Absorbance at 280 nm is a non-specific 
absorbance that was used to monitor protein, and the absorbance at 343 nm is the absorbance 
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maximum for 2-thiopyridone, which is released as HSA binds to the thiol-affinity resin.  The 
flow-through fractions, and all wash steps, were combined and reduced in volume using a speed 
vacuum system. All samples were dialyzed against deionized water to remove buffer salts and 
the 2-thiopyridone.  
A second enrichment was preformed off-column because the amount of HSA removed by 
the thiol-affinity resin was less than expected (discussed below). The resin was removed from 
the 6-ml glass columns as a slurry in phosphate buffer and was transferred to 25 ml glass vials. 
The enriched protein was reloaded onto the resin and was agitated at 200 rpm for 24 hours. To 
remove the unbound protein, the resin was transferred back to the vacuum manifold columns and 
eluted as described above. All samples were concentrated using a speed vacuum system and 
dialyzed against deionized water. Protein quantitation, before and after the enrichment 
experiments, was performed using the Bradford assay.  
Results from the protein-level enrichment experiments are shown in Figure 4.3. Based on 
total protein mass, before and after enrichment, the second enrichment was more effective in 
removing unmodified HSA than the first. The increase in the incubation time resulted in an 
approximate two fold higher binding with the resin.  When the protein was reduced prior to 
enrichment, 25-35 percent higher removal efficiency was observed.  
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Figure 4.3.  Percentage of HSA removed by the Sepharose 4B resin, with and without 
protein reduction with DTT. 
 
Additional experiments which increased contact between the protein and the resin to 48 
and 72 hours did not result in greater removal of HSA. These results suggest that 24 hours of 
contact with the resin is sufficient for removing the mercaptalbumin.  
  4.1.2. Peptide-level enrichment 
 
 HSA enriched at the protein-level was enzymatically digested using trypsin, and further 
enriched at the peptide-level. The protein-level enriched samples were treated with 8 mM DTT 
in a 0.2 M ammonium bicarbonate buffer with 8 M urea, pH 8.5, to denature and reduce the 
intramolecular disulfides. Solutions were incubated at room temperature for 30 minutes, and 
were then diluted with additional 0.2 M ammonium bicarbonate buffer to dilute the DTT and 
urea to appropriate concentrations for enzymatic digestion. Protein digestion was performed 
using 10:1 HSA to trypsin for 24 hours at 37˚C.  
After digestion, tryptic peptides were transferred to 2 KDa MWCO size exclusion spin 
columns. The spin columns were used to remove DTT, to buffer exchange to the Sepharose 6B 
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buffer, and to remove low molecular weight interfering peptides. Tryptic digests of HSA 
theoretically contain 79 peptides. The peptide of interest, containing the Cys34 modifications, 
resides on the third largest peptide (T3, MW= 2433 Da). Consequently, size exclusion can be 
used to remove many of the smaller peptides. The twelve largest peptides are shown in table 4.1. 
Since 2 KDa MWCO spin columns are not expected to precisely discriminate at their exact mass 
cutoff, peptides greater than 1500 Da are included in the table. Peptides containing cysteine 
residues were removed prior to the size exclusion step (described below) by mixing with thiol-
affinity resins. Peptides containing Cys residues are highlighted in red in Table 4.1. Note that of 
the 79 trypic peptides, only the adducted T3-Cys34 peptides and T6 peptide should remain after 
this second step of the enrichment using thiol-affinity resins, since these are the only larger 
peptides that do not have free thiols. 
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Table 4.1.  Peptide masses and amino acid sequences of the twelve largest tryptic peptides. 
Peptides containing free Cys residues are highlighted in red (Note that the T3 peptide is not 
labeled in red because unadducted Cys34-peptides have been removed at this stage). 
Peptides in red can be removed using thiol-affinity resins.  
 
 
Sepharose 6B resin was prepared using the procedure outlined above with the Sepharose 
4B resin. Sepharose 6B has the same 2-pyridyl disulfide active group as Sepharose 4B, however 
the 6B resin contains a shorter spacer arm that is more appropriate for smaller molecular weight 
species (Figure 4.4.). Tryptic peptides were incubated with the resin for 24 hours at room 
temperature. The samples were agitated at 200 rpm to prevent settling of the resin.  Following 
the peptide-level enrichment, non-bound peptides were recovered using the procedure outlined 
above in Section 4.4.1.  
 
Peptide Mass (Da) Peptide Sequence
T1 2917 SHCIAEVENDEMPADLPSLAADFVESK
T2 2593 LVRPEVDVMCTAFHDNEETFLK
T3 2433 ALVLIAFAQYLQQC34PFEDHVK
T4 2404 MPCAEDYLSVVLNQLCVLHEK
T5 2203 EFNAETFTFHADICTLSEK
T6 2045 VFDEFKPLVEEPQNLIK
T7 1916 VHTECCHGDLLECADDR
T8 1854 RPCFSALEVDETYVPK
T9 1743 HPYFYAPELLFFAK
T10 1624 DVFLGMFLYETAR
T11 1601 QNCELFEQLGEYK
T12 1512 VPQVSTPTLVEVSR
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Figure 4.4.  Chemical moieties for (A) Sepharose 6B and (B) Sepharose 4B. Note that the 2-
pyridyl disulfide active group on the distal end of each of the resins is identical. 
 
 
 
  4.1.3. Mass spectrometry 
 
 The fully-enriched protein samples were analyzed at the University of California, 
Berkeley (UCB). Two mass spectrometry platforms were used to obtain initial spectra; surface-
enhanced laser desorption ionization/time-of-flight MS (SELDI-TOF MS) and Fourier 
transform/ion cyclotron resonance MS (FT/ICR MS).  
 SELDI-TOF MS. Weak cation exchange (CM 10) and strong anion exchange (Q 10) 
ProteinChip arrays (Ciphergen Biosystems, Fremont, CA) were used to capture fractions of 
adduct-enriched peptides. ProteinChip surfaces were loaded using approximately 10 μg of 
peptides per chip. Samples were dissolved in 100 mM ammonium acetate, pH 4.5, for the CM 10 
chip arrays, and 100 mM sodium acetate, pH 8, for the Q 10 chip arrays. After incubation for 1 
hour in a humidity chamber, the chip arrays were rinsed 3 times with binding buffer and twice 
with deionized water to remove unbound peptides. Sinapinic acid, prepared in 50% acetonitrile 
and 50% trifluoroacidic acid, was added to each sample to act as an energy absorbing matrix. 
Samples were analyzed using a PBSII SELDI-TOF mass spectrometer (Ciphergen Biosystems, 
Fremont, CA). The resulting spectra are provided in figure 4.5. 
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Figure 4.5.  SELDI-TOF mass spectra of fully-enriched peptide samples. The CM 10 
ProteinChip surface has weak cation exchange properties and the Q 10 ProteinChip array 
uses strong anion exchange chemistry. 
 
 FT/ICR MS. Nanoelectrospray FT/ICR MS was employed to acquire high-resolution 
mass spectra. To reduce the salt concentrations in the peptide solutions, several solvent systems 
were explored. Peptides dissolved in 20 fold reverse-osmosis water yielded the highest quality 
spectra, and are provided in Figure 4.6. A pattern of masses differing by 22 Da was observed in 
the spectra, which is indicative of sodium adduction. Significant signal loss was encountered 
when C18 ZipTips (Millipore, Billerica, MA) were used to remove excess salt from the peptide 
samples.  
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Figure 4.6.  FT-ICR spectrum of the fully-enriched peptide sample, with the mass region of 
greatest interest expanded. The expanded mass range contains peptides with masses 
between ~2400 and 2700 Da, which corresponds with the mass of the T3 peptide (2433 Da) 
plus the anticipated adduct masses. 
 
4.1.4. Conclusions 
 
 In both the SELDI-TOF MS and FT/ICR MS experiments quality spectra were obtained 
with a large number of peaks in the 2.5 - 4.0 KDa mass range of interest (T3 MW 2433.26 + 
adducts). Substantial differences in the spectra were observed between the two mass 
spectrometry techniques. This finding was anticipated given the differences between the mass 
spectrometry platforms. For instance, the ProteinChip arrays used in SELDI-TOF experiments 
are designed to capture specific fractions of the total peptides. While this aids in increasing 
analytical sensitivity, spectra will contain different peptides depending on the chip array chosen 
for the analysis.  
 These initial results were encouraging, given this first attempt at enriching HSA-Cys34 
adducts. However, experiments are required to (1) quantify the degree of protein adduct 
enrichment, and (2) verify that the ions detected in these initial spectra were T3-Cys34 peptides.  
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To achieve the first goal, HSA was tagged with a specific Cys34 adduct, and the level of the 
modification was monitored throughout the enrichment process. This experiment is detailed in 
Section 4.2. A method to verify that MS peaks are truly derived from T3-Cys34 peptides is 
described in Section 4.3.1. 
  
 
 4.2. Assessment of adduct enrichment using BO modified HSA 
  4.2.1. Modification of HSA with BO 
 The degree of adduct enrichment achieved at both the protein and peptide levels was 
assessed using HSA modified with BO. Concentrations of HSA-Cys34-BO were quantified using 
the NCI-GC/MS method described in Section 3.3.6 (MT assay). When adducts are cleaved from 
the protein during the MT assay, the sulfur atom of HSA-Cys34 is transferred to the analyte. As a 
result, this method confirms that adducts were bound to Cys. Because Cys34 represents the only 
free thiol in intact HSA, this procedure is specific to HSA-Cys34 adducts, and will be used to 
determine adduct concentrations before and after the enrichment process. 
 One hundred mg of commercial HSA was reacted with 0.35 M BO at 37°C for 10 hours 
in 0.1 M phosphate buffer, pH 8.  Extensive dialysis was performed to remove unreacted BO. 
Aliquots were removed in triplicate and spiked with isotopically labeled S-phenyl cysteine as an 
internal standard. The level of BO modification achieved by the reaction was determined using 
the MT assay. Dilutions of the BO modified HSA were prepared with unmodified HSA to 
achieve a starting adduct concentration that provided a strong ion signal using a minimal amount 
of the protein.   
Adduct concentrations were determined to be 1.15 µmol BO/g HSA. This degree of 
modification is equivalent to ~1 BO modification in every 13 HSA molecules. Based on the ion 
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response from this sample, 10-fold dilutions were prepared and used as the starting protein in the 
enrichment experiment. This dilution factor was used because it provided an approximate S/N of 
10:1 when 100 µl of the sample was spiked onto a 1-mg HSA matrix. This procedure would 
allow the level of BO-HSA adducts to be assessed throughout the experiment using relatively 
small aliquots of HSA at each step.  
  4.2.2. Enrichment of BO adducts of HSA  
 Enrichment was performed using the general approach outlined in Sections 4.1.1 and 
4.1.2, with significant modifications to minimize sample loss, prevent protein/peptide 
precipitation, and increase the degree of enrichment. 
One hundred mg of diluted HSA-Cys34-BO was reduced with 10 mM DTT at room 
temperature for 1 hour in triplicate. The solutions were transferred to pre-conditioned 10 KDa 
MWCO spin columns to remove excess DTT and to liberate small thiols. Spin columns were 
used in this step, in place of dialysis, to minimize the time between reduction and reaction with 
the thiol-affinity resin. This modification was made to minimize the HSA auto-oxidation that can 
rapidly occur post-reduction (Ogasawara, Mukai et al. 2007). The samples were buffer-
exchanged into degassed phosphate binding buffer to prepare the samples for thiol-affinity 
enrichment.  
Reduced HSA was transferred to degassed Activated Thiol Sepharose 4B resin (prepared 
as described in section 4.1.1). Vials were capped with nitrogen and sealed with parafilm. The 
samples were incubated for 16 hours (incubation time that was determined to be optimal for 
HSA binding in previous experiments) on a shaker table at 160 rpm. Samples were eluted from 
the resin on a single Millipore disposable 22 μm filter. The resin was rinsed in batches using 80 
ml of total binding buffer under gentle vacuum. All samples were transferred to fresh 50 ml 
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polypropylene tubes and were frozen at -80ºC. The bulk volumes were lyophilized until dry, and 
were redissolved in a buffer containing 0.2 M tris-HCl, 8 M urea, pH 7.4, for enzymatic 
digestion. The mean protein recovered in each of the three samples, measured with the Bradford 
assay, was 7.9 mg. 
Peptide-level enrichment was performed using 6 mg of each sample. This step reserved 
ample protein for assessment of enrichment at the protein-level. After 8 mM TCEP was added to 
the sample buffer, the solutions were heated at 50º C for 15 minutes, to reduce the intramolecular 
disulfide bridges. Each sample was diluted with 0.2 M tris buffer to dilute the urea and TCEP 
concentrations prior to enzymatic digestion. Trypsin was added with a 10:1 substrate to enzyme 
ratio and the samples were incubated at 37º C for 3 hours. Ten KDa MWCO spin columns were 
used to remove large miscleavages, undigested protein, and trypsin prior to dialysis. Extensive 
dialysis was preformed against 4 liters of 100 mM phosphate buffer, 0.3 M NaCl, pH 7.4, using 2 
KDa MWCO dialysis tubing. The buffer was changed three times over a period of 20 hours. 
Sepharose 6B resin was prepared as described in section 4.1.2. Peptide samples were 
removed from the dialysis tubing and were transferred directly to the Sepharose 6B resin. The 
reaction vials were sealed with parafilm and were agitated at 160 rpm for 16 hours at room 
temperature. Enriched peptides were eluted from the resin using disposable Millipore 22 μm 
filters attached to a gentle vacuum. All samples were dialyzed against 4 x 4 liters of deionized 
water, and the final peptide concentrations were estimated with the Bradford assay. The Bradford 
assay was used only to obtain approximate peptide concentrations because the dye reagent used 
in the Bradford assay primarily reacts with arginine residues and less so with histidine, lysine, 
tyrosine, tryptophan, and phenylalanine. As a result, the assay response will differ depending on 
the amino acid sequence of the peptides.  
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The degree of adduct enrichment at the protein- and peptide-levels were assessed using 
the MT assay (detailed in section 3.3.6). One hundred µg of each sample was spiked into a 1 mg 
HSA matrix. Twenty-five pmol of [2H5]S-phenylcysteine was added to each sample as an 
internal standard. All samples were assayed in duplicate.  
4.2.3. Results and conclusions 
At the protein level, the degree of enrichment was anticipated to be approximately 
twelve-fold based on the total protein mass before and after enrichment. However, the true 
enrichment was determined to be 2.5-fold, based on HSA-Cys34-BO quantitation with the MT 
assay. These results indicate that, if the thiol-affinity reaction was complete, there was ~40% 
oxidized HSA remaining after the protein reduction step. These results are inconsistent with our 
previous results (Section 4.1.1), which indicated the oxidized fraction was approximately 25% of 
the total protein after reduction with DTT.  
At the peptide-level, the HSA-Cys34-BO response was below the level of detection 
(LOD). The amount of peptide used in the assay was increased 10-fold to account for a possible 
under-estimation in peptide quantitation. The response from this sample was still beneath the 
LOD. These results suggest that either the T3 peptide was lost during the peptide-level 
enrichment process, or the BO adduct was modified or lost during processing.  
  
 
 4.3. Peptide-Level Enrichment 
 Experiments were performed at the University of California, Berkeley (UCB) in the 
School of Public Health and the Department of Chemistry to investigate the loss of the T3 
peptides in the fully-enriched samples. In section 4.3.1, a ESI-MS/MS method is developed to 
monitor T3 and T3 modified peptides. In addition, experiments were performed to optimize the 
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conditions for removing small interfering peptides using size exclusion spin columns, and to 
determine how effectively the Sepharose 6B resins remove thiol containing peptides. 
4.3.1. Acquisition of T3 mass spectra  
 An ESI-MS/MS method was developed to detect T3 and modified T3 peptides, based on 
the method of Aldini et al. (Aldini, Regazzoni et al. 2008). Spectra were acquired using a triple 
quadrupole TSQ Quantum Ultra mass spectrometer equipped with a nanospray ionization source 
(Thermo Fisher Scientific, Waltham, MA). Peptides were dissolved in 50% methanol/50% 
water/0.1% formic acid (v/v/v) in 2 μM concentrations. Peptides were introduced into the mass 
spectrometer by static infusion. The nanospray ion source parameters were as follows: spray 
voltage 800 V, capillary temperature 260ºC, tube lens offset 207 V. MS/MS mass spectra were 
recorded in the positive ion mode with collision pressure set at 1.5 mTorr and collision energy 
set at 31 V. Data acquisition time was 1 minute. The MS/MS data were interpreted by manually 
comparing the acquired spectra with theoretical m/z values of the corresponding T3 peptide 
fragment ions generated from Protein Prospector v 5.3.0 (UCSF, 
http://prospector.ucsf.edu/prospector/mshome.htm). 
Product-ion scan mode was used to detect fragment ions that were specific to the T3 
peptide. Fragment ions b3, b4, and y7 were identified and used as signature fragments to confirm 
adducts were T3 in origin. These product ions were chosen based on their relative abundance and 
frequency of detection. In addition, none of the selected peptide sequence tags contain the Cys34 
moiety. As such, they are common product ions to all T3 peptides, regardless of T3-Cys34 
modifications.  A spectrum of an ESI-MS/MS product ion scan is provided in Figure 4.7. This 
MS procedure is a general approach that can be used to detect HSA-Cys34 adducts with high 
analytical sensitivity. 
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Figure 4.7.  MS/MS product-ion scan of the T3 peptide. Fragment ions b3, b4, and y7 were 
identified as peptide sequence tags. 
 
4.3.2. Evaluation of size exclusion-spin columns for removing small peptides 
 Experiments were performed to determine the efficiency of removing low molecular 
weight peptides using Amicon Ultra-4 centrifugal filter devices (Millipore, Billerica, MA). This 
step replaces the lengthy dialysis procedure used in previous experiments. Theoretically HSA 
produces 79 peptides when enzymatically digested using trypsin. Cys34 resides on the third 
largest peptide (MW 2433 + modification mass). As a result, spin filters were proposed as a 
simple means to remove low molecular weight peptides prior to treatment with thiol-affinity 
resins. This step is important because many of the smaller peptides do not possess Cys residues, 
and therefore cannot be removed via thiol-affinity covalent chromatography. 
 Fifteen-ml spin columns were employed with both 2 KDa and 3KDa MWCO capacities. 
In preliminary studies the 2 KDa MWCO did not remove as much peptide mass as expected. The 
3 KDa columns were used to determine if more peptides could be removed, without loss of the 
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T3 peptide (2433 Da). The spin filters were pre-conditioned with deionized water to remove 
filter membrane preservatives. After digesting 0.8 mg of HSA with trypsin, according to the 
conditions detailed in Section 4.1.2, the digest was divided and transferred to the spin filters in 
400-µl volumes. The volumes were diluted to 15 ml with deionized water, and were centrifuged 
at 2400 rpm until the retained volumes were reduced to 400 µl. Ten µl aliquots were removed 
from each sample; the procedure was repeated three times with aliquots removed after each spin.  
 An additional experiment was performed in parallel using the synthetic T3 peptide to 
determine if any of the peptide was lost by passage through the size exclusion filters. T3 peptide 
was dissolved in methanol, and subsequently diluted with deionized water to a final 
concentration of 30 µg/ml. Two KDa and a 3KDa MWCO spin filters were pre-conditioned with 
deionized water, and 0.3 mg of T3 peptide was added to each. The filters were centrifuged at 
2400 rpm until the retained volumes were approximately 400 µl. Ten-µl aliquots were removed 
from both the retained and the flow-through fractions for analysis. Relative peptide masses were 
determined using a nanodrop spectrophotometer measuring absorbance at 220 nm (peptide bond 
absorbance maximum). Each sample was assayed using 2-µl aliquots in triplicate.  
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Figure 4.8.  Comparison of the percentage of HSA tryptic peptides removed using 2 KDa 
versus 3 KDa MWCO spin filters.  
 
 
 
 Results from the 2 KDa versus 3 KDa MWCO spin filter experiment are shown in Figure 
4.8. The 3 KDa spin columns removed approximately 10% more mass than the 2 KDa MWCO 
columns. There was no significant difference between processing the samples three times versus 
four times. This latter finding suggests that centrifuging the samples three times was adequate to 
remove lower molecular weight peptides. The 2 KDa MWCO spin filters removed 78 to 80 
percent of the peptide mass. Although some of the sample may be loss during processing, this 
percentage is surprisingly close to the 22% of theoretical mass of tryptic peptides that are above 
2 KDa. 
 When the synthetic T3 peptide (2433 Da) was centrifuged with the 2 KDa MWCO filter 
using the same conditions described above, the absorbance in the flow-through fraction was 
below the level of detection. However, when the T3 peptide was processed with the 3 KDa 
MWCO filters, approximately 6% of the mass passed through the filter membrane into the flow-
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through fraction. These results are consistent with the results above, demonstrating that T3 
peptide loss occurs when using the higher molecular weight filters. Thus, the optimal procedure 
involved the use of 2 KDa MWCO spin filters and processing the sample three times. 
4.3.3. Evaluation of peptide removal via Sepharose 6B resin 
The peptide removal efficiency was evaluated using Sepharose 6B resin. Five mg of commercial 
HSA was enzymatically digested with trypsin using the previously described protocol (Section 
4.1.2). The resulting tryptic digest was split, and half of the sample was incubated with the thiol-
affinity resin. Prior to enrichment, a 10 KDa MWCO spin filter was used to buffer exchange the 
peptides into the Sepharose 6B binding buffer. Smaller peptides were not removed using the 2 
KDa MWCO filters to better evaluate the capacity of the resin to remove Cys containing 
peptides. Peptides were loaded onto washed and hydrated Sepharose 6B resin and incubated at 
room temperature for 1 hour. Note that sulfhydryl containing peptides were found to react 
significantly faster than the intact protein with the thiol-affinity resins, and therefore required 
substantially less incubation time. Aliquots of both the unenriched tryptic peptides, and the 
peptide-level enriched sample, were captured on a C18 ZipTips (Millipore, Billerica, MA), and 
were eluted with 70% acetonitrile. Mass spectra were acquired using a quadrupole time-of-flight 
(Q-TOF) mass spectrometer equipped with a Z-spray ion source (Q-Tof Premier, Waters, 
Milford, MA).  Ions were formed by nanoelectrospray ionization (nanoESI) from emitters made 
from borosilicate capillary tubes (1.0 mm o.d./0.78 mm i.d, Sutter Instruments, Novato, CA).  
These capillaries were pulled to a tip with an inner diameter of approximately 5-20 µm using a 
Flaming/Brown micropipette puller (Model P-87, Sutter).  The spray was initiated by applying a 
potential of 0.5 to 1 kV to a platinum wire (0.127 mm diameter, Aldrich, Milwaukee, WI) which 
was inserted into the nano ESI emitter to within approximately 2 mm of the tip.  The flow rates 
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were approximately 50 to 200 nl/min.  No back pressure was used.  The instrument parameters 
were as follows: sample cone voltage 30 V, extraction cone voltage 3.0 V, ion guide voltage 3.0 
V, source block temperature 80 ºC, accelerating voltage into the argon-filled cell 4 V, and first 
pumping stage pressure 1.5 mbar.  The distribution of positively charged sodium formate cluster 
ions formed by positive ion mode electrospray ionization, each consisting of a number of sodium 
formate units in addition to a sodium cation, was used to provide a wide range of masses of 
known value for external mass calibration (Zhou and Hamburger 1996). Mass spectra were 
processed using MassLynx software (version 4.1, Waters). The resulting spectra are provided in 
Figure 4.9. 
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Figure 4.9.  QTOF mass spectra of HSA digests, before and after peptide-level enrichment. 
Peptides identified as tryptic peptides are labeled as T peptides. Letters A through N 
correspond with tryptic peptide fragments. All peptides containing Cys residues are shown 
in red, and all peptides that do not contain Cys are shown in blue. 
 
 
 
 Theoretical maps of tryptic peptides, which included peptides from up to five 
miscleavages, were generated using ProteinProspector (version 4.27.2 basic, The Regents of the 
University of California). The ProteinProspector generated peptides included trypsin autolysis 
products. Tryptic peptides, identified on the basis of theoretical masses, are labeled in the spectra 
as T2, T6, T16 and T21. Peptides identified as miscleaved fragments are labeled A through N.  
m/z
Pe
rc
en
t I
nt
en
si
ty
 
T6
T2
A
B
C
D
E
F
m/z
T6
Pe
rc
en
t I
nt
en
si
ty
 T21
T16
T12G
H
I J
K
N
L
M
Pre-Enrichment
Post-Enrichment
75 
 
All peptides and peptide fragments containing Cys residues are shown in red, whereas peptides 
without Cys are labeled in blue. Amino acid sequences are provided for each peptide in Table 
4.2. 
   
Table 4.2.  Masses and amino acid sequences of probable tryptic peptides and tryptic 
peptide fragments that were identified using ProteinProspector, version 4.27.2 basic. 
     
 
In the pre-enriched peptides two tryptic peptides were identified, T6 and T2. In addition, 
six miscleaved peptides were identified. All of the identified peptides in the pre-enriched sample 
contain Cys residues, with the exception of T6. After enrichment, three tryptic peptides were 
identified in the spectrum; T6, T12, and T21. In addition, eight miscleaved peptides were 
identified. With exception of one minor peptide (M), none of the identified peptides in the post-
Peptide 
ID
m/z Amino acid sequence
T2 2594 LVRPEVDVMCTAFHDNEETFLK
T6 2045 VFDEFKPLVEEPQNLIK
T16 1343 AVMDDFAAFVEK
T21 1150 LVNEVTEFAK
A 2622 EQLKAVMDDFAAFVEKCCKADDK
B 2736 LVRPEVDVVMCTAFHDNEETFLKK
C 2920 ATKEQLKAVMDDFAAFVEKCCKADDK
D 3138 HPEAKRMPCAEDYLSVVLNQLCVLHEK
E 3243 AVMDDFAAFVEKCCKADDKETCFAEEGKK
F 3429 HPYFAPELLFFAKRYKAAFTECCQAADK
G 880 AEFAEVSK
H 985 TYETTLEK
I 1075 LDELRDEGK
J 1343 AVMDDFAAFVEK
K 1519 LDELRDEGKASSAK
L 1640 KVPQVSTPTLVEVSR
M 1705 RYKAAFTECCQAADK
N 2289 QTALVELVKHKPKATKEQLK
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enriched samples contained Cys residues. These results provide conclusive evidence that the 
thiol-affinity resins are highly effective in removing peptides containing free sulfhydryls, while 
permitting peptides without Cys to be recovered. It is notable that while T6 is a very minor peak 
in the pre-enriched sample, it becomes the ion with the greatest intensity in the post-enriched 
spectrum. Since the T6 peptide is the only non-Cys containing peptide that is above 2 KDa in 
mass (the mass cutoff for the spin filters), it was anticipated to be the most abundant interfering 
peptide after treatment with thiol-affinity resins and removal of small peptides.  
4.3.4. Non-selective T3 peptide binding to Sepharose 6B resin 
 Experiments were performed to determine if peptides were lost during incubation with 
the Sepharose 6B resin due to non-specific binding. Two different synthetic peptides were used 
in this experiment; the HSA T3 tryptic peptide (MW 2433.3), and a tryptic 14-mer from the β-
subunit of Hb (MW 1420.7 Da). Because both peptides contained sulfhydryl gro ups and should 
specifically bind to the thiol-affinity resin, the peptides were partially modified with 
iodoacetamide (IAA) to assess non-specific binding. In this experiment, the unmodified peptides 
should form disulfides with the thiol-affinity resins, whereas the IAA modified proteins should 
be recovered in the flow-through fraction. Reactions were performed in PBS using 25 mM IAA 
for 90 minutes at 37ºC.  The degree of IAA modification was assessed using the ESI-MS/MS 
method described in section 4.3.1. Based on these results, the modified peptides were combined 
with unmodified peptides to create a solution with an approximate 70:30 ratio, respectively. The 
peptide mixtures were then reacted with Sepharose 6B resin using the previously described 
conditions. Mass spectra were acquired pre- and post-enrichment using peptides collected on 
ZipTips via direct infusion (ESI-MS/MS conditions detailed in Section 4.3.1.). 
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 Spectra of the Hb 14-mer peptide are provided before and after reaction with the thiol-
affinity resin in Figure 4.10. In panel A, a full scan spectrum of the 14-mer is displayed pre-
enrichment.  The triply and doubly charged ions are labeled for both the modified peptide 
(494.30 Da and 740.58 Da) and the unmodified peptide (474.63 Da and 711.53 Da), respectively. 
A full-scan spectrum is provided after incubation with the thiol-affinity resin in panel B. The 
unmodified 14-mer was well resolved in the pre-enriched sample. In contrast, after enrichment 
the unmodified peptide was not detected. Panels C and D show the modified peptide before and 
after enrichment in selective ion monitoring mode (SIM). These spectra are provided to illustrate 
the high recovery of the adducted peptide after reaction with the resin. Total ion current (TIC) 
plots are shown above the spectra, where the loss in total ion intensity is approximately 25% 
after enrichment.  
                            
Figure 4.10.  Spectra of the hemoglobin 14-mer peptide before and after enrichment with 
the thiol-affinity resin. Panels A and B provide full-scan spectra of the modified and 
unmodified peptide, where the unmodified peptide is completely removed in the pot-
enriched spectrum. Panels C and D are SIM spectra of the modified peptide that 
demonstrate the peptide is recovered from the resin with high yield. 
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 Unlike the Hb 14-mer peptide, the modified HSA T3 peptide was almost completely lost 
during incubation with the Sepharose 6B resin due to non-selective binding, and was not 
detected in the post-enriched spectrum. To determine whether the adducted peptide could be 
recovered from the resin, several elution conditions were explored. In each case, the fully-
modified IAA-T3 peptide was incubated with Sepharose 6B. Post-reaction, the resin was washed 
using a series of extraction solutions with various percentages of acetonitrile (ACN). A SIM 
spectrum of the fully-modified IAA-T3 peptide is shown in Figure 4.11 before reaction with the 
resin. 
 
                 
Figure 4.11.  SIM spectra of the predominant +3 ions of the unmodified and        modified 
T3 peptides before incubation with Sepharose 6B. 
 
 After incubation with the resin, the modified T3 peptide was recovered with high yield 
using 70% ACN. Because the T3 peptide is an unusually hydrophobic peptide (discussed below), 
we hypothesize that the T3 peptide was non-selectively lost on the Sepharose 6B resin through 
van der Waals interactions. Spectra are provided in Figure 4.12 before and after enrichment, 
using 70% ACN to elute the peptide after incubation. Although recovery of the T3 peptide 
requires an additional elution step due to the non-specific binding to the resin, this non-selective 
interaction may provide additional enrichment by further isolating the T3 peptide from less 
hydrophobic peptides with do not interact with the resin. 
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Figure 4.12.  SIM spectra of the fully-modified IAA-T3 peptide before and after reaction 
with Sepharose 6B resin. After incubation with the resin, the peptide was eluted using 70% 
ACN. 
 
4.3.5. T3 peptide loss through precipitation 
 In addition to losing the T3 peptide during incubation with the Sepharose 6B resin, 
substantial loss was encountered during other stages of the enrichment protocol. Precipitation 
was visibly observed under several conditions, especially preceding the reaction with the 
Sepharose 6B resin. When tryptic digests were used, as opposed to the synthetic T3 peptide 
alone, loss of the T3 peptide was confirmed using ESI-MS/MS (method detailed in Section 
4.3.1.). In many experiments the precipitate appeared as tiny fibers. Once the fibers were 
observed, the precipitate could not be resolubilzed, even with solvent conditions that dissolved 
the T3 peptide prior to precipitation. This observation led us to question whether the T3 peptide 
could be oligermerizing as amyloid-type fibrils. The HSA T3 peptide is unique in that 12 of the 
21 amino acid residues are hydrophobic (Figure 4.13.). In addition to having almost 60% 
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hydrophobic residues, modifications on Cys34 can contribute to the hydrophobicity of T3, 
depending on the physicochemical nature of the adduct. Other peptides with excessive 
hydrophobic sequences have been observed to form unique aggregates that can result in 
irreversible precipitation. This phenomenon has been extensively studied in association with the 
deposition of amyloid fibrils in neurodegenerative diseases, including Alzheimer’s disease 
(Tjernberg, Lilliehook et al. 1997; Thirumalai, Klimov et al. 2003; Britschgi, Olin et al. 2009). 
Although low resolution structures of such aggregates have been determined, little is known at 
the molecular level about the oligomerization process (Harper and Lansbury 1997; Rochet and 
Lansbury 2000). However, the large number of consecutive hydrophobic residues on T3 is 
consistent with amyloidogenic fibril moieties (Kelly 1998; Rochet and Lansbury 2000; Britschgi, 
Olin et al. 2009). Because the likelihood of amyloid-type aggregation, and the morphology of the 
formed oligomers, depends on peptide concentration, temperature, pH, and salt concentration 
(Thirumalai, Klimov et al. 2003), conditions were explored using the T3 peptide that avoid 
peptide loss due to precipitation. 
 
                              
Figure 4.13.  Amino acid sequence of the HSA tryptic T3 peptide. Residues                          
in red have hydrophobic R groups. The hydrophobicity of Cys34 is dependent                     
on the physicochemical nature of the modification. 
 
 Several conditions were found that readily dissolved the T3 peptide. The dried T3 peptide 
could be solubilized by first dissolving the peptide in methanol. Once the peptide was completely 
dissolved, water could be added to a final concentration of approximately 60% water. In 
addition, the T3 peptide was soluble in acetonitrile (ACN). These conditions were compatible 
21ALVLIAFAQYLQQC34PFEDHVK41
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downstream of the enrichment process, when analysis of the peptides was made via direct 
infusion; However, these conditions were not compatible with the LC-MS conditions, which 
required an initial lower percentage of organic solvant. To address this limitation, suitable 
aqueous conditions were explored by adjusting the acidity of the Sepharose 6B buffer.  Under 
highly acidic conditions (pH 3), the synthetic peptide remained in solution. However, regardless 
of the conditions used to solubilize the T3 peptide (on its own or within HSA tryptic digests), 
loss of signal was observed overtime that was generally unpredictable. 
 
 
 4.4. Conclusions 
 
 In the initial studies outlined in Section 4.1, we provide an overview of our novel 
approach for enriching and detecting protein adducts of HSA-Cys34. Following on these initial 
experiments, a specific GC/MS approach was used to quantify the degree of enrichment using 
HSA modified with BO (see Section 4.2). These results indicated that adducts were enriched 
approximately 2.5 fold at the protein-level; however, the T3 peptide adducts were lost during the 
peptide enrichment phase. To explore this loss of T3 peptide adducts, targeted experiments were 
performed using IAA modified HSA. A general mass spectrometry approach was developed to 
track the enrichment process, that is applicable to any stable HSA-Cys34 modification. These 
experiments were detailed in Section 4.3.  
Based on these results, our method provides a general approach to detect stable 
modifications on HSA-Cys34 with high analytical sensitivity. Although enrichment at both the 
protein and peptide levels theoretically provides the greatest degree of enrichment, the peptide-
level enrichment procedure was inconsistent, often resulting in significant analyte loss. Further 
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studies are required to fully characterize the stability of the T3 peptide under the peptide-level 
enrichment conditions. 
  Additional experiments were performed to optimize the protein-level enrichment 
procedure. Some of the conditions that were optimized include (1) conditions for reducing HSA, 
(2) the required amount of Sepharose 4B, and (3) the duration of contact time needed for HSA 
and the thiol-affinity resin. Lengthy dialysis steps were replaced with spin filter procedures to 
increase sample throughput, and the entire procedure was scaled down to minimize the amount 
of sample required for the assay. In the initial enrichment experiments several weeks were 
required to fully enrich a single sample of 100 mg of HSA. In our final procedure, HSA-Cys34 
adducts are enriched and analyzed in two days, and require less than 0.5 mg of starting protein. 
Our final protein adduct enrichment method is presented in Section 5.
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5. Paper II.  Enrichment of Cysteinyl Adducts of Human Serum Albumin as 
Biomarkers of Exposure [Funk, W., Li, H, Lavarone, A., Williams, E., Riby, J., Rappaport, 
S., Biochemical Journal (Submitted)]   
 
 
 5.1 Abstract 
Protein adducts can serve as biomarkers of exposure to a host of xenobiotic toxicants and 
reactive endogenous molecular species. In this study, we report a novel method to enrich 
cysteinyl adducts of human serum albumin (HSA), which provides greater analytical sensitivity 
to detect adducts of low abundance.  Because the major site of adduction of HSA is the single 
free sulfhydryl group located at Cys34, the enrichment approach takes advantage of the 
propensity of mercaptalbumin (i.e., unadducted HSA) to bind with thiol-affinity resins. 
Furthermore, because the most common adducts of HSA-Cys34 are mixed disulfides formed by 
reversible reactions between Cys34 and serum thiols (notably cysteine), mixed disulfides were 
liberated via reduction with dithiothreitol (DTT) prior to reacting mercaptalbumin with thiol 
affinity resins.  Reduction with DTT was judged to be more effective than that with tris(2-
carboxyethyl)phosphine (TCEP) in preliminary experiments. Mass spectrometry employing 
electrospray ionization was used to detect mercaptalbumin and HSA-Cys34 modifications before 
and after treatment of HSA with thiol-affinity resins.  Prior to reduction of mixed thiols, 
differences in the adduct content were detected across samples of freshly isolated HSA, archived 
HSA (stored at -80oC for 11 y), and commercial HSA.  Cysteinylated and glycosylated adducts 
were present in all types of HSA with relative abundances decreasing in the order commercial 
HSA > archived HSA > fresh HSA.  After thiol reduction and treatment with thiol-affinity resin
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the mass corresponding to mercaptalbumin was no longer observed in mass spectra of HSA 
samples.  The HSA content of pre- and post-enrichment HSA samples was quantified by 
measuring total proteins with the Bradford assay and gel electrophoresis.  After removal of 
mercaptalbumin, the protein content of post-enrichment samples reflected the quantity of 
adducted HSA-Cys34 in those samples.  The ratio of the amount of HSA adducts to the amount of 
HSA prior to enrichment was 0.029 mg adducts/mg HSA in fresh HSA and was 0.323 mg 
adducts/mg HSA in archived HSA.  The elevated adduct levels in the archived samples could be 
due in part to differences in specimen preparation and storage, rather than to differences in levels 
of circulating electrophiles.  Interestingly, archived specimens pooled from nonsmoking subjects 
had marginally greater adduct levels than those pooled from smoking subjects (p = 0.057, n = 
14). These results indicate that thiol-affinity resins provide a straightforward means for removing 
mercaptalbumin from HSA samples in studies to characterize protein adducts of reactive 
chemicals in the blood.  
 
 5.2 Introduction 
It has been suggested that biomarkers of exposure should be used in studies of the effects 
of toxic chemicals on human health (Wild 2009). Biomonitoring can also provide a more precise 
estimate of internal dose, which decreases increases the power to detect relationships between 
adverse health effects and causal agents (Lin, Kupper et al. 2005). However, because 
environmental toxicants are often chemically reactive electrophiles, their short life spans in vivo 
make them difficult to measure directly in biological media.  This has motivated the use of stable 
adducts of these compounds, and/or their metabolites, with abundant blood proteins, notably 
hemoglobin and human serum albumin (HSA), as exposure biomarkers (reviewed by Tornqvist  
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et al., (Tornqvist, Fred et al. 2002); and Rubino et al., (Rubino, Pitton et al. 2009)). Stable 
adducts accumulate over the mean residence time of a protein and thereby reflect the integral of 
the blood level of the reactive species over 28 d for human serum albumin (HSA) and 60 d for 
hemoglobin. 
Human serum albumin contains 35 cysteine residues, 34 of which are bound as 
intramolecular disulfides.  Although the remaining cysteine, Cys34, has the only free sulfhydryl 
group in HSA, it represents the largest fraction of thiols in serum (Fabisiak, Sedlov et al. 2002), 
where it has been estimated to account for approximately 80% of the antioxidant capacity 
(Ogasawara, Mukai et al. 2007; Marjolaine, Rondeau et al. 2008). Within the tertiary protein 
structure of HSA, Cys34 resides in a unique microenvironment close to three ionizable residues: 
Asp38, His39, and Asp38 (Stewart, Blindauer et al. 2005).  As a result, Cys34 has an unusually low 
pKa (<6.7 compared to about 8.0 - 8.5 for thiols in most other proteins and peptides) and exists 
primarily in the highly nucleophilic thiolate form (Stewart, Blindauer et al. 2005).  Examples of 
the many chemical species that form adducts with Cys34 include oxirane and quinone metabolites 
of benzene, naphthalene, and pentachlorophenol (Yeowell-O'Connell, Rothman et al. 1998; 
Waidyanatha, Rothman et al. 2004; Waidyanatha, Sangaiah et al. 2005) (Waidyanatha, Lin et al. 
1996; Tsai, Lin et al. 2002), nitrogen mustards (Noort, Hulst et al. 2002), 4-hydroxy-trans-2-
nonenal, 2-propenal, malondialdehyde, glyoxal, and other products of lipid peroxidation (Aldini, 
Dalle-Donne et al. 2006; Aldini, Gamberoni et al. 2006; Aldini, Regazzoni et al. 2008), metal 
ions such as Ag+, Hg2+, and Au+, and a host of drugs including auranofin, D-penicillamine, 
ethacrynate, and cisplatin (reviewed by (Kragh-Hansen, Chuang et al. 2002)).  Yet, although 
some HSA-Cys34 adducts have been detected in studies of humans and animals, the analytical 
matrix is complex and the levels of measured individual adducts have been very low (less than 
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one in a million unadducted protein molecules (Rubino, Pitton et al. 2009)).  The combination of 
matrix effects plus low abundance has made it difficult to simultaneously measure numerous 
HSA adducts in samples of human serum and to identify unknown adducts. 
Here we report a novel method to selectively enrich Cys34 adducts in fresh or archived 
samples of HSA. The enrichment approach takes advantage of the propensity of HSA with 
unmodified Cys34 (mercaptalbumin) to bind with thiol-affinity resins (Haugen 1989). Because 
adducted HSA is comprised primarily of small mixed-disulfides that exhibit reversible binding 
with HSA-Cys34, disulfide adducts were reduced to mercaptalbumin by dithiothreitol (DTT) 
prior to treatment with thiol-affinity resins.  Using electrospray ionization (ESI) mass 
spectrometry, we characterized intact HSA from various sources and investigated the effects of 
reduction of mixed disulfides on the enrichment process.  Enrichment was assessed both by mass 
spectrometry of the intact proteins and also by quantifying the amounts of HSA via the Bradford 
assay and gel electrophoresis before and after use of thiol-affinity resins. 
 
 5.3. Experimental Section 
  5.3.1. Chemicals 
 Dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP), iodoacetamide (IAA), 
phosphate buffered saline, Activated Thiol Sepharose 4B, sequence grade trypsin, sodium 
chloride, calcium chloride, ammonium sulfate, nitrogen, BioRad reagent dye, sodium dodecyl 
sulfate, BioSafe Coomassie G-250 dye (Bio-Rad, Hercules, CA), ammonium sulfate, Tris base, 
ProteasMAX, acetonitrile (Fisher Optima grade, 99.9%) and formic acid (Pierce, 1 ml ampoules, 
99+%) were purchased from Fisher Scientific (Pittsburgh, PA).  Commercial HSA was from 
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Sigma (St. Louis, MO).  Water was purified to a resistivity of 18.2 MΩ·cm (at 25 °C) using a 
Milli-Q Gradient ultrapure water purification system (Millipore, Billerica, MA).   
 
  5.3.2. Isolation of HSA  
 Four ml of whole blood were obtained from a healthy Asian volunteer subject (age = 34 
y) by venipuncture in heparin.  The blood was immediately centrifuged for 15 minutes at 3000 x 
g. The plasma layer was transferred to a 15-ml centrifuge tube, and saturated ammonium sulfate 
was added drop-wise to a final concentration of 60% ammonium sulfate. The plasma was 
vortexed briefly and centrifuged for 30 minutes at 3000 x g to pellet the precipitated protein. The 
supernatant, containing HSA, was transferred to 10-kDa molecular weight cutoff (MWCO) spin 
columns (Amicon Ultra-4, Millipore, Billerica, MA) and the protein was desalted using 5 x 15-
ml volumes of deionized water. The isolated HSA was immediately aliquoted and frozen at -
80°C. Archived HSA from 40 volunteer subjects (pooled and balanced from males/females, 
smokers/nonsmokers, and black/white subjects) had previously been isolated according to a 
similar protocol (Lin, McKelvey et al. 2006), which included dialysis to remove small 
molecules, lyophilization to constant weight, and dissolving the purified HSA in deionized water 
at 50 mg/ml.  Archived samples were stored at -80oC prior to processing in the current study.  
  5.3.3. MS characterization of HSA 
 The heterogeneity of HSA with respect to Cys34-adduct status was evaluated in freshly 
isolated and archived HSA (described above), and commercial HSA from Sigma-Aldrich.  
Protein samples were analyzed using an Agilent 1200 series liquid chromatograph (LC; Santa 
Clara, CA) that was connected in-line with an LTQ Orbitrap XL hybrid mass spectrometer 
equipped with an Ion Max electrospray ionization source (ESI; Thermo Fisher Scientific,  
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Waltham, MA). The LC was equipped with C8 guard (Poroshell 300SB-C8, 5 μm, 12.5 × 2.1-
mm, Agilent) and analytical (75 × 0.5-m) columns and a 100-μl sample loop.  Solvent A was 
0.1% formic acid/99.9% water and solvent B was 0.1% formic acid/99.9% acetonitrile (v/v). For 
each sample, approximately 50 to 100 pmol of protein analyte was injected onto the column 
using an Agilent 1200 autosampler. Following sample injection, analyte trapping was performed 
for 5 min with 99.5% A at a flow rate of 90 μl/min. The elution program consisted of a linear 
gradient from 25% to 95% B over 34 min, isocratic conditions at 95% B for 5 min, a linear 
gradient to 0.5% B over 1 min, and then isocratic conditions at 0.5% B for 14 min, at a flow rate 
of 90 μl/min. The column and sample compartments were maintained at 35 ºC and 10 ºC, 
respectively. Solvent (Milli-Q water) blanks were run between samples, and the autosampler 
injection needle was rinsed with Milli-Q water after each sample injection, to avoid cross-
contamination between samples. The mass spectrometer ESI source parameters were as follows: 
ion transfer capillary temperature 275 ºC, normalized sheath gas (nitrogen) flow rate 25%, ESI 
voltage 2.0 kV, ion transfer capillary voltage 33 V, and tube lens voltage 125 V. Mass spectra 
were recorded in the positive ion mode over the range m/z = 500 to 2000 using the Orbitrap mass 
analyzer, in profile format, with full MS automatic gain control target settings of 3 × 104 and 5 × 
105 charges for the linear ion trap and the Orbitrap, respectively, and an Orbitrap resolution 
setting of 6 × 104 (at m/z = 400, FWHM). Raw mass spectra were processed using Xcalibur 
software (version 4.1, Thermo) and measured charge state distributions were deconvoluted using 
ProMass software (version 2.5 SR-1, Novatia, Monmouth Junction, NJ), using the default “large 
protein” parameters and a background subtraction factor of 1.5.  Week-to-week reproducibility 
of the measured masses of intact, adducted HSA proteins was within ± 3 Da. 
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  5.3.4. Reduction of HSA mixed disulfides 
The efficiency of reducing small mixed disulfides bound to HSA-Cys34 was investigated 
with both DTT and TCEP.  One-mg portions of commercial HSA were treated with one of 11 
different concentrations of DTT or TCEP that ranged from equimolar to 270-fold molar excess, 
with reaction times ranging from 5 to 60 minutes. All experiments were conducted at room 
temperature in phosphate buffer, pH 7.4. Following protein reduction, samples were reacted with 
iodoacetamide (IAA), and the degree of reduction was assessed by monitoring the number of 
IAA additions (+57 Da per modification) above the nominal mass of HSA (66,436±3 Da) (Beck, 
Ambahera et al. 2004; Kleinova, Belgacem et al. 2005). Reduction status was assessed before 
and after reduction using a LTQ Orbitrap XL hybrid mass spectrometer under the same MS 
conditions described above.  Reduction conditions were considered optimal when they were 
stringent enough to reduce the Cys34-mixed disulfides while also preserving the intramolecular 
disulfide linkages.  
For enrichment experiments, 2-mg portions of fresh HSA (n = 6) and 0.5-mg portions of 
archived HSA (n = 16) were reduced using a 2.7-fold molar excess of DTT to release Cys34-
bound mixed disulfides in 1-ml and 0.5-ml volumes, respectively.  This concentration of DTT 
had been found to be optimal in preliminary experiments with commercial HSA (described 
above). 
 5.3.5. Using IAA-modified HSA as a positive control 
 IAA was reacted with HSA to create a Cys34 adduct that would serve as a positive control 
for the enrichment experiments. Commercial HSA was treated with a 2.7 molar excess of DTT 
and was reacted with 150 mM IAA in phosphate buffer, pH 7.4, at 37°C for 1 h.  After removing 
excess IAA and buffer salts with a 10-kDa MWCO spin column, the fully-modified HSA was 
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diluted with freshly isolated HSA to produce a starting solution containing 0.047 mg of the IAA-
modified HSA per mg of HSA.   
  5.3.6. Using thiol-affinity resins to remove mercaptalbumin from HSA 
 A slurry containing 75 mg or 250 mg (dry mass) of Activated Thiol Sepharose 4B 
hydrated resin in degassed 4B binding buffer (100 mM Tris-HCl, 0.5 M NaCl, pH 7.4) was 
prepared in a ratio of 75% settled medium to 25% buffer for the archived and fresh HSA 
samples, respectively.  The slurry was transferred to a 1.5-ml polypropylene spin tube containing 
cellulose acetate membranes with a 0.22-µm pore size (Pierce Spin Cups, Thermo Scientific, 
Pittsburgh, PA).  The reduced HSA starting solution, containing either fresh or archived HSA 
was added to the resin, mixed by vortexing, capped with nitrogen, and sealed with Parafilm®.  
After incubating at room temperature for 16 h on a rotary suspension mixer, the unbound 
proteins were removed from the thiol-affinity medium by centrifuging at 7000 rpm for 5 
minutes. The flow-through fraction containing the HSA-Cys34 adducts was recovered.   
  5.3.7.  Quantitation of total proteins and HSA 
 Mass spectrometry employing electrospray ionization was used to detect mercaptalbumin 
and HSA-Cys34 modifications before and after treatment of HSA with thiol-affinity resins. The 
total amounts of proteins in all pre- and post-enrichment samples were determined in duplicate 
with the Bradford assay according to the standard microtiter plate protocol from the 
manufacturer (Bio-Rad, Hercules, CA) using commercial HSA for the standard curve.  The 
purity of the isolated HSA was determined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Aliquots containing 10 µg of total protein in 10 µl of deionized 
water were mixed with 10 µl of 2X Laemmli sample buffer (Bio-Rad, Hercules, CA) containing 
10% SDS and 5% BME and boiled for 10 min.  The denatured samples and prestained molecular 
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weight markers (Precision-Plus Protein Standards, Bio-Rad) were loaded on 4 – 20% 
polyacrylamide gradient gels (NuSep, Lawrenceville, GA) and separated at 100 V for one hour.  
The gels were stained with Bio-Safe Coomassie G-250 dye (Bio-Rad) and the relative 
concentrations of the various protein bands were determined by densitometry using an 
AlphaImager HP (Alpha Innotech, San Leandro, CA).  The purity of HSA was expressed as the 
percentage of the sum of all protein bands. 
  5.3.8. Estimation of adduct levels in HSA samples 
 The HSA content of samples before and after removal of mercaptalbumin by thiol-
affinity resins was quantified by measuring total proteins with the Bradford assay and gel 
electrophoresis (described above).  After removal of mercaptalbumin, the protein content of post-
enrichment samples reflected the quantity of adducted HSA-Cys34.  Proportions of HSA adducts 
were therefore estimated as ratios of mean quantities of HSA after thiol-affinity treatment to 
those observed before treatment (mg adducts/mg HSA).  For freshly-isolated HSA that had been 
spiked with IAA-modified HSA (positive control), this ratio was adjusted by subtracting the 
proportion of IAA adducts that had been added (0.047 mg IAA adducts/mg HSA).   
 
 5.4. Results and discussion 
  5.4.1. Heterogeneity of HSA 
Human serum albumin is heterogeneous with respect to the thiol redox state, and exists in 
both the reduced and oxidized forms. The degree of HSA oxidation in vivo has been reported to 
increase with oxidative stress and various disease conditions, suggesting that HSA functions as 
an important scavenger of reactive systemic oxidants (Kawakami, Kubota et al. 2006; Turell, 
Carballal et al. 2009). However, after collection of blood specimens, Cys34 can be further 
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oxidized during sample storage and processing.  In particular, oxidation of Cys34 has been 
observed to initiate addition reactions with cysteine, and mixed disulfides (Sengupta, Chen et al. 
2001; Beck, Ambahera et al. 2004; Kawakami, Kubota et al. 2006; Ogasawara, Namai et al. 
2006).   
 In this study, the degree of HSA-Cys34 modification was examined for three different 
HSA preparations: freshly isolated HSA, archived HSA, and commercial HSA.  As shown in 
Figure 1, ESI mass spectrometry of the intact proteins points to different adduct profiles for these 
three sources of HSA.  The spectrum of freshly isolated HSA (Figure 1A) was dominated by the 
mass corresponding to mercaptalbumin (66,436 Da), with a few lower abundance masses also 
observed, including one at 66,556 Da representing HSA+Cys and another at 66,599 Da, 
corresponding to HSA+Gluc (the glycosylated product).  [Since the primary site for 
nonenzymatic glycosylation is Lys (Shaklai, Garlick et al. 1984; Kisugi, Kouzuma et al. 2007), 
glycosylation should not preclude modifications of Cys34].  Commercial HSA contained the 
largest fraction of HSA+Cys, which was twice as abundant as mercaptalbumin (Figure 2B).  The 
ESI mass spectrum of commercial HSA also showed lower abundant masses at 66,473 Da, 
consistent with NO modification, and at 66,512 Da (modification unknown).  In the archived 
HSA spectrum, mercaptalbumin was the most abundant species (Figure 1C).  However, 
prominent peaks corresponding to cysteinylation and glycosylation were also observed at higher 
levels than observed in the fresh HSA sample. 
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Figure 5.1.   Deconvoluted ESI mass spectra showing heterogeneity of HSA from various 
sources. (A) Freshly isolated HSA; (B) commercial HSA, and (C) HSA stored at -80oC for 
11 years. Mercaptalbumin (66,436 Da) is the most abundant species in fresh HSA (A), with 
minor peaks at 66,556 Da and 66,599 Da, corresponding to cysteinylation and 
glycosylation, respectively. Commercial HSA (B) was the most highly oxidized of the three 
HSA preparations. The most abundant modification was from cysteinylated (66,556 Da), 
with peaks at 66,473 and 66,593 Da consistent with the addition of NO and glucose, 
respectively. Archived HSA (C) displayed elevated cysteinylation (66,556 Da) and 
glycosylation (66,590 Da), and also contained an unknown abundant modification at 66,496 
(+60) Da. The modification at 66,496 Da appears to be an irreversible modification at 
Cys34.  The asterisks in (B) denote masses of 66,473 Da and 66,512 Da. 
 
 
 
 5.4.2. Reduction of HSA-Cys34 mixed disulfides 
The enrichment of HSA adducts of reactive electrophiles can be maximized by reducing 
mixed thiol disulfides to mercaptalbumin prior to treatment with thiol-affinity resins.  We 
explored the reduction of mixed thiol disulfides using DTT and TCEP at room temperature with 
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1-mg specimens of commercial HSA.  Eleven different concentrations of DTT or TCEP were 
tested that ranged from a molar equivalent of reducing agent to 270-fold molar excess, with 
reaction times ranging from 5 to 60 minutes. These results are shown in Figure 2.  The reaction 
time did not have a significant effect in any of the experiments using TCEP or DTT (data not 
shown) 
 
  
Figure 5.2.   Reduction of commercial HSA using TCEP and DTT. In the bottom panel, 
optimal reduction conditions are labeled corresponding to the addition of one IAA 
molecule. In the upper panel, deconvoluted ESI mass spectra illustrate (A) optimal 
conditions using 2.7 molar excess DTT and (B) more stringent reduction conditions using 
270 molar excess DTT. In spectrum A, peaks at 66,493 and 66,654 Da correspond to HSA-
Cys34-IAA and HSA-Cys34-IAA+Gluc, respectively. The peak at 66,554 Da is thought to 
represent a pool of irreversible adducts. In spectrum B, the series of ~57 Da mass additions 
indicate reduction of intermolecular disulfide linkages, with the addition of 2 IAA 
molecules representing a broken disulfide. 
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When commercial HSA was treated with TCEP at concentrations ranging from molar 
equivalence to a 270-fold molar excess, between two and five intramolecular disulfides were 
cleaved, corresponding to 5 – 11 IAA modifications, respectively. In contrast, no intramolecular 
disulfides were broken with DTT at concentrations between 2.7- and 10.8-fold molar excess. As 
illustrated in Figure 2A, incubation of commercial HSA with a 2.7-fold molar excess of DTT 
effectively reduced Cys34-mixed disulfides, while preserving the intramolecular disulfide 
linkages.  The most intense peak in the deconvoluted ESI mass spectrum was at 66,493 Da, 
corresponding to HSA with a single IAA modification.  A second abundant peak was observed at 
66,554 Da.  Although this latter modification (a mass addition of 118 Da) is consistent with the 
addition of a second IAA molecule, this peak was also observed in spectra from HSA that had 
not been treated with IAA. In addition, for IAA to modify a second cysteine on HSA, an 
intramolecular disulfide linkage would have to be broken. This acetylation pattern would result 
in a mass at 66,611 Da (plus two IAA molecules) in addition to the observed peak at 66,554 Da, 
because a single reduced intramolecular disulfide would result in two free thiols. Thus, the 
evidence supports the conclusion that Cys34 was the only cysteine residue reduced under these 
conditions. Other masses in this spectrum occurred at 66,654 Da, which is consistent with 
glycosylated HSA-Cys34-IAA, and a minor peak was observed between 66,554 Da and 66,654 
Da, which is consistent with glycosylated mercaptalbumin. The latter suggests that a small 
fraction of HSA was not modified with IAA.   
At a 27-fold molar excess of DTT, commercial HSA was modified with two additional 
IAA molecules, indicating one broken intramolecular disulfide. As shown in Figure 2B, two 
additional intramolecular disulfides were reduced when DTT concentrations reached 270-fold 
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excess.  Under these conditions, a series of peaks were observed with mass differences of 
approximately 57 Da, representing additions of 1 to 6 IAA molecules. 
Based on these results, a 2.7 fold molar excess of DTT was selected for reducing mixed 
disulfides without disrupting the intramolecular disulfide bridges. Reactions were performed at 
room temperature for 5 minutes. These reduction conditions are consistent with previous studies 
(Aldini, Vistoli et al. 2008).  
 5.4.3. Qualitative Assessment of HSA-Cys34 Adduct Enrichment 
Figure 3 shows the deconvoluted ESI mass spectra of HSA before and after enrichment 
of the Cys34 adducts with thiol-affinity resins. Three prominent peaks were observed in the pre-
enrichment spectrum at 66,436, 66,556, and 66,599 Da, corresponding to HSA, HSA+Cys and 
HSA+Gluc, respectively, consistent with previous findings (Beck, Ambahera et al. 2004; Bar-Or, 
Bar-Or et al. 2005). After enrichment, three abundant peaks were observed in the spectrum at 
66,493, 66,545, and 66,705 Da. The first peak at 66,493 (+57) Da corresponds to HSA-Cys34-
IAA (positive control), which was not resolved in the pre-enrichment spectrum, where the 
starting concentration of HSA-Cys34-IAA was 0.047 mg/mg HSA. The most intense peak in the 
post-enrichment spectrum (Figure 3B) was at 66,545 Da, which corresponds to a mass addition 
of 109 Da.  In the three-dimensional structure of HSA, the Cys34 residue resides in a cleft that is 
about 10 Å deep (He and Carter, 1992), which can sterically limit access to this residue by large 
electrophiles.  It is therefore reasonable to expect Cys34 adducts that are of limited mass, i.e., 109 
Da.   
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Figure 5.3.   Deconvoluted ESI mass spectra of fresh HSA (A) before and (B) after 
treatment with thiol-affinity resins (0.047 mg/mg HSA-Cys34-IAA was added prior to 
enrichment as a positive control). In the pre-enrichment sample,(A), peaks were observed 
at 66,436, 66,556, and 66,599 Da, corresponding to mercaptalbumin, cysteinylated HSA, 
and glycosylated HSA, respectively. After enrichment, (B), a peak was observed at 66,493 
Da for the HSA -Cys34-IAA positive control, which was not detected before enrichment. 
Peaks at 66,545 and 66,705 Da are thought to represent a pool of Cys34 and glycosylated 
Cys34 irreversible adducts, respectively. Note that no peak corresponding to unmodified 
HSA was observed after treatment with thiol-affinity resins. 
 
 
A peak at 66,705 (66,545 + 160) Da was also observed in the post-enrichment spectrum. 
This probably represents the corresponding pool of N-linked glycosylated HSA-Cys34 adducts. 
Because all of the ions resolved in the post-enriched spectrum were adducted HSA-Cys34 
species, it appears that treatment of HSA with thiol affinity resins effectively removed 
mercaptalbumin.  
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5.4.4. Quantitative assessment of HSA-Cys34 before and after treatment with 
thiol-affinity resins 
The amount of HSA in each sample was calculated using the Bradford assay to measure 
total protein, and SDS-PAGE to determine the purity of HSA in each sample. SDS-PAGE 
images are shown pre- and post-enrichment in Figure 4. Before treatment with thiol-affinity 
resins, the fresh HSA sample contained 70.6% HSA, and the archived HSA had a mean purity of 
46.9% (SD 6.8). After treatment, the mean purity was 67.6% (SD 4.0) and 68.4% (SD 9.7) for 
the fresh and archived HSA, respectively. The archived HSA may have been altered during the 
isolation process (where dialysis and lyophilization were used) or may have degraded over time 
(11 y at -80oC), thus resulting in the observed lower HSA purity.  Further work will be needed to 
determine the effects of HSA isolation and storage on levels of HSA-Cys34 adducts.  After 
enrichment, the purity of the fresh and archived HSA specimens were similar, suggesting that the 
thiol-affinity resin removed the lower molecular weight contaminants from the archived HSA. 
One fresh HSA specimen (sample 1.5 in Figure 4), and two of the pooled archived 
samples (one of the duplicate samples of samples 6 and 9 in Figure 4), were excluded from 
analysis due to low volumetric and protein recoveries after treatment with thiol-affinity resins.  
The estimated mean adduct level for fresh HSA was 0.076 mg (SD 0.010) after enrichment. 
When the amount of HSA-Cys34-IAA positive control was subtracted from these values (0.047 
mg), the mean adduct level was 0.029 mg. The estimated mean adduct level in the archived 
specimens was 0.323 mg (SD 0.059), which was much higher than in freshly isolated HSA.  
Adduct levels in the archived samples were marginally higher in nonsmoking subjects (mean = 
0.349 mg/mg HSA) compared to smoking subjects (mean = 0.289 mg/mg HSA) (p = 0.057).  
Since we expected to observe higher adduct levels in smoking subjects compared to control 
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subjects, interpretation of the apparent increase in adduct levels among nonsmokers must await 
information about the identities of the particular adducts involved.  No statistical differences 
were observed in adduct levels between either male and female subjects or black and white 
subjects (p > 0.10). 
 
                
Figure 5.4.   SDS-PAGE images of HSA before and after enrichment.  Before Enrichment 
(upper panel): fresh HSA is labeled as ID 1 and pooled archived HSA is labeled with IDs 2 
- 9. After Enrichment (lower panel): pooled archived HSA is labeled with IDs 2 - 9 and 
fresh HSA samples are labeled with IDs 1.1 - 1.6. 
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 5.5. Conclusions 
Protein adducts can serve as biomarkers of exposure to a host of xenobiotic toxicants, and 
reactive endogenous species.  However, because the levels of protein adducts are small 
compared to the unmodified proteins, they are difficult to detect and identify without prior 
enrichment.  In this study, we present a novel method to enrich cysteinyl adducts of HSA by 
removing mercaptalbumin (i.e., unadducted HSA) with thiol-affinity resins.  This approach 
should allow many adducts of reactive electrophiles to be measured at the HSA-Cys34 locus.  
Since this is the most nucleophilic reaction site in serum, the method should have general 
applicability for measuring adducts of systemic importance, at least for relatively small 
adducting species. 
Prior to adduct enrichment, HSA was reduced to release Cys34-bound mixed disulfides. 
Of the many reducing conditions explored with DTT and TCEP, a 2.7-fold molar excess of DTT 
was determined to be optimal for releasing small thiols, while preserving the intramolecular 
disulfide linkages in HSA.  As seen in Figure 2A, after HSA was reduced with DTT, the bulk of 
HSA was mercaptalbumin. Prior to reduction, the most abundant modification on HSA-Cys34 
was cysteinylation.  Although cysteinylation was relatively minor in freshly isolated HSA (the 
66,556 Da component in Figure 1A), higher levels of cysteinylated HSA was observed in the 
archived samples (66,556 Da; Figure 1C). As such, it is important to reduce HSA prior to 
treatment with thiol-affinity resins to achieve maximum enrichment of non-disulfide adducts. 
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Table 5.1.   Amounts of Human Serum Albumin (HSA) Measured after Enrichment in 
Fresh and Archived Samples. (HSA-Cys34 adducts are represented by the amounts of HSA 
after enrichment by treatment with thiol-affinity resins). 
               
                
 
Using mass spectrometry, we demonstrated that treatment of HSA with thiol-affinity 
resins effectively removed mercaptalbumin from the samples (Figure 3).  Based upon 
measurements of total proteins before and after treatment, we observed about 10 times higher 
levels of non-disulfide adducts in archived specimens of HSA compared to fresh HSA (Table 1).  
This points to the possibility that HSA-Cys34 had been modified during either isolation or storage 
(11 y at -80oC), or both.  Because archived specimens will often be used to characterize adduct 
levels associated with chemical exposures, it is important to determine the exact nature of 
modifications to HSA-Cys34 that occur during isolation and storage.
Subject
or Pool
Type of 
HSA
Smoker Gender Race HSA.
(mg)
Adducts 
(mg/mg HSA)a
1 Fresh No M A 1.41 0.079 b
1 Fresh No M A 1.41 0.065 b
1 Fresh No M A 1.41 0.071 b
1 Fresh No M A 1.41 0.074 b
1 Fresh No M A 1.41 0.091 b
2 Archived No F B 0.262 0.357
2 Archived No F B 0.262 0.295
3 Archived No F W 0.212 0.304
3 Archived No F W 0.212 0.278
4 Archived No M W 0.214 0.331
4 Archived No M W 0.214 0.346
5 Archived No M W 0.184 0.460
5 Archived No M W 0.184 0.419
6 Archived Yes F B 0.274 0.296
7 Archived Yes F W 0.264 0.259
7 Archived Yes F W 0.264 0.315
8 Archived Yes M B 0.261 0.305
8 Archived Yes M B 0.261 0.321
9 Archived Yes M W 0.208 0.237
Legend: M=male, F=female, A=Asian, B=black, W=white.
a HSA measured after treatment with thiol-affinity resins.
b Includes 0.047 mg IAA-HSA/mg HSA (positive control).
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6.  Discussion and Conclusions  
 
 6.1. Summary of scientific contributions 
 
 Two novel methods were developed in this dissertation research. The first is a method to 
measure protein adducts in DBS which acts to extend the use of protein adducts as exposure 
measures to large-scale epidemiological studies. In addition, measurement of protein adducts in 
DBS opens the possibility to access exposures during fetal growth, a critical stage of human 
development that is highly sensitive to chemical assault. Fetal exposures can be monitored by 
utilizing vast archives of residual newborn DBS that exist in the US and around the world. 
 The second method developed in this thesis is a procedure to enrich protein adducts, 
which provides greater analytical sensitivity to detect lower abundant adducts. This method is a 
general approach which enriches cysteinyl adducts of HSA, thus providing a deeper view into 
the HSA-Cys34 adductome. Because chronic exposure to environmental toxicants tend to be low, 
relative to workplace exposures, this approach aims to extend protein adducts to environmental 
epidemiology as biomarkers of exposure. 
 
 6.2. Suggestions for future research 
 
  6.2.1. Enrichment of protein adducts in DBS 
 
 This work is presented as two distinct analytical methods, though it is important to note 
that the two procedures are highly complementary. While we chose to isolate Hb in DBS for 
adduct analysis, DBS could also be used to obtain HSA. A single DBS contains approximately 1 
mg of HSA, which is greater than twice the amount of protein required in our adduct enrichment 
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procedure. HSA purified from DBS specimens could be enriched for HSA-Cys34 adducts, and 
used to achieve higher analytical sensitivity to detect exposures to chemical toxicants.  
To extend the adduct enrichment protocol to DBS, a method must first be developed to 
recover HSA from DBS that will provide both high protein recovery and purity. Our current 
DBS protein isolation protocol could be altered to optimize for HSA purity by using higher 
ethanol concentrations during precipitation. However, it is unlikely adequate protein purity can 
be achieved using this single step, given the large abundance of Hb in the DBS matrix. In 
addition, a HSA isolation method would need to be robust with respect to DBS storage. In the 
current DBS procedure, total protein recovery rapidly declined in specimens that were stored for 
greater than 6 months. This limitation would limit the use of DBS in studies using archived 
specimens. This is especially restricting in cases involving newborn DBS, which may have been 
stored for years under less than ideal conditions. 
Once a procedure has been developed to isolate HSA from DBS that circumvents the 
current protein isolation limitations, DBS repositories can be exploited to examine links between 
specific prenatal exposures and childhood diseases.  
  6.2.2. Protein adductiomics: an ‘omics’ approach to biomarker discovery 
 
Protein adducts can serve as biomarkers of exposure to a wide array of xenobiotic 
toxicants and reactive endogenous species. However, despite their widespread application in 
occupational and environmental toxicology, more global analytical approaches have been largely 
neglected for the discovery of new biomarkers. Systems biology techniques have been utilized in 
genomics, proteomics, and metabolomics to globally profile genes and gene mutations, protein 
expression, and metabolites, respectively (MacGregor 2004; Baak and Mohan 2007; Tan, 
Lambros et al. 2007; Zhang, Wei et al. 2007). However, despite these large initiatives, the 
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protein adductome has yet to be exploited in this manner. Because the HSA-Cys34 adductome is 
comprised extensively of reactive electrophiles, which are compounds that have been implicated 
with many adverse health endpoints, its utility as a unique biological entity for ‘omics’ 
experiments deserves attention.  
Many assays have been developed to measure specific protein modifications as exposure 
biomarkers. These methods typically focus on the measurement of single adducts, or at best, 
small numbers of adducts at a given time. Adducts that are monitored in these assays are chosen 
a priori, based on suspected exposures to given toxicants. Because of sensitivity constraints, 
these assays typically mandate the use of selective ion monitoring. As such, the analytical 
approaches used tend to be highly specific to the analytes of interest. Although these assays can 
be highly sensitive, they do not lend themselves well to discovery-type experiments, where the 
identity of the modification is unknown.  
Examples of more general approaches to measure protein adducts are very limited. Noort 
et al, reported a generic mass spectrometry approach to verify exposure to organophosphates, 
based on pepsin digestion of butyrylcholinesterase to a common precursor peptide (Noort, Fidder 
et al. 2006). Michael adducts of reactive carbonyls on HSA-Cys34 have also been monitored 
using neutral loss scans (Beck, Ambahera et al. 2004; Aldini, Gamberoni et al. 2006; Aldini, 
Regazzoni et al. 2008). A similar approach has been reported by Orioli et al. to measure peptides 
with histidine residues in the urine of genetically obese rats (Orioli, Aldini et al. 2007). Aldini et 
al. investigated a precursor ion scan strategy to detect HSA-Cys34 modifications on the 
tryptic/chymotryptic peptide 31LQQCPF36 (Aldini, Orioli et al. 2007). Although the study by 
Aldini et al. is perhaps the best example of how an ‘omics’ approach could be used to measure 
protein adducts, the authors did not report levels of any adducts in unmodified HSA. So, despite 
105 
 
these recent efforts measuring protein/peptide modifications using more general strategies, true 
systems biology approaches for discovering candidate biomarkers are still pending.  
In this dissertation a method is presented for enriching cysteinyl adducts of HSA (Section 
5). In addition, a non-adduct specific MS approach is described for monitoring HSA-Cys34 
modifications with high analytical sensitivity (Section 4.3.1). These methods are suitable for true 
omics investigations, and can be used in discovery experiments to identify new exposure 
biomarkers. Adducts can be profiled using a multi-stage mass spectrometry approach. In the first 
stage, adduct-enriched HSA specimens can be enzymatically digested using trypsin, and mass 
spectra can be acquired using high resolution ESI-LC-MS/MS (e.g. Orbitrap or FT-ICR MS) in 
full-scan mode to identify candidate peptides. The peptides can be further characterized in 
product-ion scan mode, using fragment ions b3, b4, and y7 as signature fragments (described in 
Section 4.3.1) to confirm adducts reside on the T3 peptide. Accurate masses can be then 
generated to determine the elemental composition of the unknown modifications, and adducts 
can be proposed based on probable molecular structures. Identities of the adducts can be 
confirmed using synthesized T3 adducted peptides; matching retention times, masses, and MS 
fragmentation patterns. This global approach profiling the Cys34 adductome has significant 
potential in generating novel biomarkers of exposure, and identifying causal agents associated 
with human diseases.  
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